

# CITATION REPORT

List of articles citing

A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer

DOI: 10.1056/nejm199010043231403

New England Journal of Medicine, 1990, 323, 940-5.

**Source:** <https://exaly.com/paper-pdf/21838970/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1049	When is a cancer treatment worthwhile?. <i>New England Journal of Medicine</i> , <b>1990</b> , 323, 989-90	59.2	18
1048	Role of systemic therapy in advanced non-small-cell lung cancer. <b>1990</b> , 89, 777-86		12
1047	The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. <b>1991</b> , 52, 35-84		252
1046	Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer. ATTIT (Association pour le Traitement des Tumeurs Intra-Thoraciques). <b>1991</b> , 27, 1238-42		8
1045	Controversies in the treatment of non-small cell lung cancer. <b>1991</b> , 27, 362-6		12
1044	Chemotherapy combined with chest irradiation for locally advanced non-small cell lung cancer. <b>1991</b> , 115, 737-9		8
1043	Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. <b>1991</b> , 115, 681-6		149
1042	Chemotherapy for non-small cell lung cancer. The continuing challenge. <b>1991</b> , 99, 1326-8		22
1041	Primary, adjuvant, and palliative radiation therapy. <b>1991</b> , 100, 841-5		
1040	Non-small cell lung cancer. Part II: Treatment. <b>1991</b> , 15, 105-54		43
1039	ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Fédération Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists. <b>1991</b> , 20, 1183-90		231
1038	Induction chemotherapy for non-small cell carcinoma of the lung: limitations and lessons. <b>1991</b> , 20, 1375-6		8
1037	Comparison of the Radiation Therapy Oncology Group and American Joint Committee on Cancer staging systems among patients with non-small cell lung cancer receiving hyperfractionated radiation therapy. A report of the Radiation Therapy Oncology Group protocol 83-11. <b>1991</b> , 68, 509-16		22
1036	Neoadjuvant cisplatin plus vinblastine chemotherapy in locally advanced non-small cell lung cancer. <b>1991</b> , 68, 1216-20		11
1035	Results of treatment and lessons learned from pathologically staged T4 non-small cell lung cancer. <b>1991</b> , 47, 209-14		10
1034	Unresectable stage III non-small-cell lung cancer: lessons and directions from clinical trials research. <b>1991</b> , 83, 382-3		10
1033	Critical analysis of neoadjuvant therapy for Stage IIIa non-small cell lung cancer [corrected]. <b>1991</b> , 143, 889-94		25

1032	Recent outcomes for patients with carcinoma of the lung. <b>1991</b> , 9, 9-17		13
1031	Chemotherapy and radiation therapy as compared with radiation therapy in stage III non-small-cell cancer. <i>New England Journal of Medicine</i> , <b>1991</b> , 324, 1136-7	59.2	12
1030	Chemotherapy of lung cancer. <i>New England Journal of Medicine</i> , <b>1992</b> , 327, 1434-41	59.2	323
1029	Controversies in the nonsurgical treatment of stage III non-small cell lung cancer. <b>1992</b> , 145, 967-77		38
1028	Progress against rare and not-so-rare cancers. <i>New England Journal of Medicine</i> , <b>1992</b> , 326, 563-5	59.2	12
1027	Treatment of non-small-cell lung cancer with cisplatin and radiotherapy. <i>New England Journal of Medicine</i> , <b>1992</b> , 327, 432; author reply 433	59.2	1
1026	Combined-modality therapies for non-small cell lung cancer. <b>1992</b> , 3 Suppl 3, 3-10		4
1025	Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. <i>New England Journal of Medicine</i> , <b>1992</b> , 326, 524-30	59.2	1074
1024	Recent Developments in the Treatment of Lung Cancer. <b>1992</b> , 267, 1661		9
1023	Lung cancer. <i>BMJ: British Medical Journal</i> , <b>1992</b> , 304, 1298-301		7
1022	Advances in treatment of loco-regionally advanced lung cancer and the ACCP. A common ground. <b>1992</b> , 101, 1070-3		1
1021	When to stop a clinical trial. <i>BMJ: British Medical Journal</i> , <b>1992</b> , 305, 235-40		165
1020	Editorial Comments. <b>1992</b> , 148, 306-307		
1019	Innovative therapies in hematology and oncology. <b>1992</b> , 76, 1169-84		
1018	Endobronchial irradiation with 192Ir in the treatment of malignant endobronchial obstruction. <b>1992</b> , 102, 1072-4		16
1017	The antitumor activity of radiation therapy is reduced in patients with non-small-cell carcinoma of the lung refractory to chemotherapy. <b>1992</b> , 3, 273-6		3
1016	Cross resistance between radiotherapy and chemotherapy in cancer treatment: what can be done about it?. <b>1992</b> , 3, 254-5		1
1015	Non small cell carcinoma of the lung. A retrospective study. Presented at the 41st annual meeting of the Royal Australasian College of Radiologists, September 1990, Perth. <b>1992</b> , 36, 243-8		4

1014	Clinical practice of radiotherapy. <b>1992</b> , 339, 159-63	25
1013	Current options in the treatment of non-small cell lung cancer. <b>1992</b> , 44 Suppl 4, 46-59	10
1012	Advances in lung cancer?. <b>1992</b> , 59, 145-9	1
1011	Combination of 5-FU cisplatin and hypofractionated irradiation followed by split-course radiotherapy in 47 patients with unresectable non small cell lung cancer. <b>1992</b> , 25, 186-91	3
1010	Surgical treatment for higher stage non-small cell lung cancer. <b>1992</b> , 54, 999-1013	86
1009	Investigation Chemotherapy in Multimodality Therapy of Non-Small Cell Lung Cancer. <b>1992</b> , 26, 64-71	
1008	Lung cancer: a review of current therapeutic modalities. <b>1992</b> , 170, 249-65	20
1007	Phase II study of Edatrexate in stage III and IV non-small-cell lung cancer. <b>1992</b> , 30, 465-8	29
1006	Opportunity cost--a neglected aspect of cancer treatment. <b>1992</b> , 65, 309-10	16
1005	Induction chemotherapy for non-small cell lung cancer with clinically evident mediastinal node metastases: the role of postoperative radiotherapy. <b>1992</b> , 23, 605-13	12
1004	Treatment of non-small cell lung cancer with external beam radiotherapy and high dose rate brachytherapy. <b>1992</b> , 23, 127-32	83
1003	The role of radiation therapy in the treatment of brain metastases. <b>1992</b> , 23, 229-38	134
1002	Response to Dr. Speiser. <b>1992</b> , 23, 251-252	
1001	Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. <b>1992</b> , 24, 11-5	149
1000	Combined modality therapy for stage III non-small cell lung carcinoma: results of treatment and patterns of failure. <b>1992</b> , 24, 17-23	21
999	Adverse influence of younger age on outcome in patients with non-small cell lung carcinoma (NSCLC) treated with radiation therapy (RT) alone. <b>1992</b> , 24, 37-42	14
998	Can lung cancer be cured by irradiation alone?. <b>1992</b> , 24, 181-2	5
997	Is concomitant cisplatin and radiotherapy more efficacious treatment than radiotherapy alone in stage III non-small cell lung cancer?. <b>1992</b> , 24, 185-6	3

996	Should patients with post-resection locoregional recurrence of lung cancer receive aggressive therapy?. <b>1992</b> , 24, 25-30	54
995	Comparison of outcome between clinically staged, unresected superior sulcus tumors and other stage III non-small cell lung carcinomas treated with radiation therapy alone. <b>1992</b> , 69, 363-9	13
994	Clinical stage II non-small cell lung cancer treated with radiation therapy alone. The significance of clinically staged ipsilateral hilar adenopathy (N1 disease). <b>1992</b> , 70, 2410-7	53
993	A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study. <b>1993</b> , 72, 62-8	9
992	Effect of radiologic stage III substage on nonsurgical therapy of non-small cell lung cancer. <b>1993</b> , 72, 1588-96	20
991	Hypofractionated radiation therapy in unresectable stage III non-small cell lung cancer. <b>1993</b> , 72, 1885-93	25
990	Results of high-dose thoracic irradiation incorporating beam's eye view display in non-small cell lung cancer: a retrospective multivariate analysis. <b>1993</b> , 27, 273-84	68
989	Three-dimensional conformal radiation therapy may improve the therapeutic ratio of high dose radiation therapy for lung cancer. <b>1993</b> , 26, 685-9	116
988	Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. <b>1993</b> , 27, 493-8	174
987	Neutron vs. photon radiation therapy for inoperable regional non-small cell lung cancer: results of a multicenter randomized trial. <b>1993</b> , 27, 499-505	20
986	Is a nihilist approach to lung cancer still justified?. <b>1993</b> , 27, 747-8	
985	Editor's note. <b>1993</b> , 26, 379-380	
984	A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno, and large cell carcinoma of the lung: report of Radiation Therapy Oncology Group 84-07. <b>1993</b> , 26, 459-68	50
983	Simultaneous chemoradiation in advanced non-small cell lung cancer. <b>1993</b> , 9, 120-6	
982	Long-term results of combined modality therapy for esophageal cancer. <b>1993</b> , 1, 227-234	2
981	Statistical and ethical issues in monitoring clinical trials. <b>1993</b> , 12, 1459-69; discussion 1471-5	56
980	Stopping rules, interim analyses and data monitoring committees. <b>1993</b> , 68, 1047-50	9
979	Extended resection for higher-stage non-small-cell lung cancer. <b>1993</b> , 17, 719-28	11

978	Postoperative chemotherapy for resected non-small-cell lung cancer. <b>1993</b> , 17, 735-40	1
977	Radiotherapy in the management of non-small-cell lung cancer. <b>1993</b> , 17, 741-50	4
976	Longer survival with higher doses of thoracic radiotherapy in patients with limited non-small cell lung cancer. <b>1993</b> , 25, 599-604	39
975	Combined Betaseron R (recombinant human interferon beta) and radiation for inoperable non-small cell lung cancer. <b>1993</b> , 27, 613-9	33
974	Preoperative concomitant cisplatin/VP16 and radiotherapy in stage III non-small cell lung cancer. <b>1993</b> , 27, 621-5	14
973	Radiation and simultaneous cisplatin in non-small cell lung cancer. <b>1993</b> , 27, 739-46	6
972	Report of phase II trial of concurrent chemoradiotherapy with radical thoracic irradiation (60 Gy), infusional fluorouracil, bolus cisplatin and etoposide for clinical stage IIIB and bulky IIIA non-small cell lung cancer. <b>1993</b> , 26, 469-78	22
971	The MIC regimen in non-small cell lung cancer. <b>1993</b> , 9, 81-89	24
970	A comparative overview of non-small cell lung cancer: 1980 versus 1991. <b>1993</b> , 9, 15-24	1
969	Cisplatin and continuous infusion vindesine and 5-fluorouracil in non-small cell lung cancer (NSCLC) (ATTIT 002). ATTIT (Association pour le Traitement des Tumeurs Intra-Thoraciques). <b>1993</b> , 29A, 1914-5	
968	Primary chemotherapy in stage IIIA non-small cell lung cancer patients with clinically apparent mediastinal lymph node metastases: focus on five-year survivors. <b>1993</b> , 9, 369-376	5
967	Future developments in radiation oncology for the management of carcinoma of the lung. <b>1993</b> , 9, 81-87	15
966	Rationale for the treatment of non-small cell lung cancer. <b>1993</b> , 9, 5-14	8
965	Role of radiation therapy in the management of lung cancer. <b>1993</b> , 68, 593-602	7
964	Combined modality therapy for stage IIIA non-small cell carcinoma of the lung. <b>1993</b> , 29A, 511-5	20
963	Continuous, hyperfractionated, accelerated radiotherapy (CHART) in non-small cell lung cancer. <b>1993</b> , 9, 221-228	12
962	The radiation therapy oncology group experience altered fractionation in lung cancer. <b>1993</b> , 9, 229-238	4
961	Analysis of early and late deaths on RTOG non-small cell carcinoma of the lung trials: comparison with CALGB 8433. <b>1993</b> , 10, 189-97	11

960	Carboplatin, etoposide, and radiotherapy, followed by surgery, for the treatment of marginally resectable non-small cell lung cancer. <b>1993</b> , 19 Suppl C, 53-62	19
959	Induction chemotherapy prior to definitive radiation for Stages IIIA and IIIB non-small cell lung cancer. <b>1993</b> , 9, 39-47	6
958	Treatment of locally advanced non-small cell lung cancer. <b>1993</b> , 9, 49-60	3
957	Current treatment of unresectable lung cancer. <b>1993</b> , 68, 603-11	42
956	Multimodality therapy for non-small cell lung cancer: the role of surgery. <b>1993</b> , 9, 25-30	5
955	Preoperative chemotherapy for locally advanced non-small cell lung cancer. <b>1993</b> , 9, 31-37	3
954	Future directions in the management of non-small cell lung cancer. <b>1993</b> , 9, 91-107	10
953	Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. <b>1993</b> , 55, 1365-73; discussion 1373-4	300
952	Rational Integration of Radiation and Chemotherapy in Patients with Unresectable Stage IIIA or IIIB NSCLC. <b>1993</b> , 103, 35S-42S	2
951	Multimodality therapy for stage IIIA (N2) lung cancer. An overview. <b>1993</b> , 103, 356S-359S	20
950	Chemotherapy and radiotherapy for regionally advanced non-small-cell lung cancer. <b>1993</b> , 103, 362S-366S	14
949	Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group. <b>1993</b> , 85, 299-306	143
948	The case for mitomycin in non-small cell lung cancer. <b>1993</b> , 50 Suppl 1, 35-50	20
947	Low-versus high-energy photon beams in radiotherapy for lung cancer. <b>1993</b> , 18, 65-72	0
946	Induction Therapy Followed by Definitive Local Control for Stage III Non-Small-Cell Lung Cancer. <b>1993</b> , 103, 43S-50S	2
945	Induction Chemoradiotherapy Followed by Surgery for Stage III Non-small Cell Lung Cancer. <b>1993</b> ,	
944	Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small-cell lung cancer. <b>1993</b> , 4, 847-51	35
943	Cisplatin plus epirubicin and etoposide followed by irradiation plus lonidamine in stage III nonsmall cell lung cancer. <b>1993</b> , 50, 10-3	4

942	FOM: An Effective, Non-Cisplatin-Based Combination Chemotherapy for Advanced Non-Small-Cell Lung Cancer with Low Toxicity. <b>1993</b> , 16, 100-105	
941	Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. <b>1993</b> , 105, 97-106	155
940	Zur Rolle der Chemotherapie beim nichtkleinzelligen Bronchialkarzinom (NSCLC) im Tumorstadium III. <b>1994</b> , 17, 294-302	2
939	Lung Cancer Surgery. <b>1994</b> , 154, 2397	13
938	Randomized Phase 2 Evaluation of Preoperative Radiation Therapy and Preoperative Chemotherapy with Mitomycin, Vinblastine, and Cisplatin in Patients With Technically Unresectable Stage IIIA and IIIB Non-small Cell Cancer of the Lung. <b>1994</b> , 106, 348S-354S	1
937	Hyperfractionated split-course thoracic radiation-therapy plus chemotherapy in locally advanced nonsmall cell lung-cancer. <b>1994</b> , 4, 577-82	
936	El N2 en el c�ncer de pulm�n: Una frontera en litigio. <b>1994</b> , 30, 121-123	0
935	Chemotherapy plus surgery versus surgery alone in non-small-cell lung cancer. <i>New England Journal of Medicine</i> , <b>1994</b> , 330, 1756; author reply 1757	59.2 3
934	A path through the forest. <b>1994</b> , 12, 360-1	
933	Alternating irradiation and chemotherapy in stage III A and B nonsmall cell lung cancer: report of a cancer and Leukemia Group B phase II study 8636. <b>1994</b> , 29, 1085-8	5
932	Radiation therapy with concomitant continuous infusion cisplatin for unresectable nonsmall cell lung carcinoma. <b>1994</b> , 28, 1251-6	8
931	Stopping a clinical trial early: frequentist and Bayesian approaches applied to a CALGB trial in non-small-cell lung cancer. <b>1994</b> , 13, 1313-27	25
930	Some practical aspects of the interim monitoring of clinical trials. <b>1994</b> , 13, 1401-9	26
929	Surgery after radiochemotherapy for stage III lung cancer: postoperative complications and late results. <b>1994</b> , 56, 2-6	7
928	Continuous-infusion cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer. <b>1994</b> , 73, 1171-6	9
927	Combined modality treatment using BID radiation for locally advanced non-small cell lung carcinoma. <b>1994</b> , 73, 2599-606	7
926	Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer. <b>1994</b> , 74, 1243-52	53
925	Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer. <b>1994</b> , 74, 1874-81	9



924	Inoperable non-small cell lung cancer: a retrospective analysis of 427 patients treated with high-dose radiotherapy. <b>1994</b> , 28, 583-8	37
923	Review of the curative role of radiotherapy in the treatment of non-small cell lung cancer. <b>1994</b> , 11, 153-78	30
922	Does adjuvant chemotherapy decrease distant metastasis formation in patients with non-small cell lung cancer?. <b>1994</b> , 10 Suppl 1, S187-94	3
921	Adjuvant and neoadjuvant therapy for stages I through III non-small cell lung cancer. <b>1994</b> , 58, 899-900	33
920	Neoadjuvant therapy: a novel and effective treatment for stage IIIb non-small cell lung cancer. Southwest Oncology Group. <b>1994</b> , 58, 290-4; discussion 294-5	63
919	Radiosensitization by cytotoxic drugs. The EORTC experience by the Radiotherapy and Lung Cancer Cooperative Groups. <b>1994</b> , 10 Suppl 1, S263-70	21
918	Pitfalls and biases in the reporting and interpretation of the results of clinical trials. <b>1994</b> , 10 Suppl 1, S143-50	5
917	The role of induction chemotherapy before radiation therapy in non-operative management of stage III NSCLC. <b>1994</b> , 11 Suppl 3, S55-65	3
916	Concurrent chemotherapy (CT) and radiotherapy (RT) in locally advanced non-small cell lung cancer (NSCLC): a review. <b>1994</b> , 11 Suppl 3, S79-99	11
915	Dose intensity of radiation therapy in non-small cell carcinoma of the lung: a review of RTOG data and strategies. <b>1994</b> , 10 Suppl 1, S161-6	5
914	Challenges of preoperative chemotherapy in non-small cell lung cancer. <b>1994</b> , 10 Suppl 1, S195-203	
913	Concomitant chemoradiotherapy for non-small cell lung cancer. <b>1994</b> , 10 Suppl 1, S253-61	2
912	Combined modality treatment for locally advanced non-small cell lung cancer--which control arm?. <b>1994</b> , 10 Suppl 1, S231-8	1
911	Variations in the management and outcome of non-small cell lung cancer in Ontario. <b>1994</b> , 32, 106-15	38
910	Toxicity of combined radiation and chemotherapy in non-small cell lung cancer. <b>1994</b> , 10 Suppl 1, S271-80	18
909	Is the use of chemotherapy justified in non-small-cell lung cancer?. <b>1994</b> , 4, 1-8	6
908	The aged patient with lung cancer. Management recommendations. <b>1994</b> , 4, 34-46	13
907	A feasibility study of extended chemotherapy for locally advanced non-small cell lung cancer: a phase II trial of cancer and leukemia group B. <b>1994</b> , 12, 273-82	23

906	Current status of neoadjuvant therapy for non-small cell lung cancer. <b>1994</b> , 106, 355S-358S	5
905	Future directions in clinical research for lung cancer. <b>1994</b> , 106, 399S-407S	10
904	Radiotherapy planning for lung cancer: can we do better?. <b>1994</b> , 38, 303-4	1
903	Hypofractionated irradiation for inoperable non-small cell lung cancer. <b>1995</b> , 39, 265-70	18
902	Should non-small cell carcinoma of the lung be treated with chemotherapy? Pro: chemotherapy is for non-small cell lung cancer. <b>1995</b> , 151, 1285-7	16
901	Strategy for dose escalation using 3-dimensional conformal radiation therapy for lung cancer. <b>1995</b> , 6, 693-7	76
900	Continuous carboplatin infusion during 6 weeks' radiotherapy in locally inoperable non-small-cell lung cancer: a phase I and pharmacokinetic study. <b>1995</b> , 72, 992-7	9
899	Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. <b>1995</b> , 71, 366-70	147
898	Thoracoscopy and video-assisted thoracic surgery in the treatment of lung cancer. <b>1995</b> , 107, 298S-301S	11
897	Decline of posttreatment tumor marker levels after therapy of nonsmall cell lung cancer. A useful outcome predictor. <b>1995</b> , 75, 1586-93	13
896	Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Results of Radiation Therapy Oncology Group 90-15. <b>1995</b> , 75, 2337-44	70
895	Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer. <b>1995</b> , 76, 530-1	1
894	Turning up the heat on nonsmall cell lung cancer: is the toxicity of concurrent cisplatin-based chemotherapy and accelerated fractionation acceptable?. <b>1995</b> , 31, 431-3	2
893	Evolution and accomplishments of the Radiation Therapy Oncology Group. <b>1995</b> , 33, 747-54	9
892	The treatment of stage III nonsmall cell lung cancer using high dose conformal radiotherapy. <b>1995</b> , 33, 1001-7	54
891	Preliminary results of a prospective trial using three dimensional radiotherapy for lung cancer. <b>1995</b> , 33, 993-1000	108
890	Development of multifield three-dimensional conformal radiotherapy of lung cancer using a total lung dose/volume histogram. <b>1995</b> , 3, 243-255	14
889	Phase I/II study of treatment of locally advanced (T3/T4) non-oat cell lung cancer with concomitant boost radiotherapy by the Radiation Therapy Oncology Group (RTOG 83-12): long-term results. <b>1995</b> , 31, 819-25	47

888	Mitomycin, cisplatin, and vindesine followed by radiotherapy combined with cisplatin in stage III nonsmall cell lung cancer: long-term results. <b>1995</b> , 31, 813-8		7
887	Chemoradiation in advanced nonsmall cell lung cancer. <b>1995</b> , 33, 183-8		7
886	The evolution of Radiation Therapy Oncology Group (RTOG) protocols for nonsmall cell lung cancer. <b>1995</b> , 32, 1513-25		33
885	Interferon gamma and thoracic irradiation in the treatment of unresectable stage IIIA/B non-small cell lung cancer. <b>1995</b> , 32, 271-2		2
884	Defining the role of chemotherapy in non-small-cell lung cancer. <b>1995</b> , 6, 317-8		7
883	Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. <i>Journal of Clinical Oncology</i> , <b>1995</b> , 13, 1425-9	2.2	117
882	Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>1995</b> , 13, 1609-14	2.2	137
881	Does knowledge guide practice? Another look at the management of non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>1995</b> , 13, 1904-11	2.2	90
880	Abstracts. <b>1995</b> , 13, 1-61		
879	Issues at the cutting edge in stage III non-small-cell lung cancer. <b>1995</b> , 6 Suppl 3, S33-6		1
878	The role of induction therapy and surgery for stage IIIA lung cancer. <b>1995</b> , 6 Suppl 3, S29-32		6
877	Adjuvant and neo-adjuvant chemotherapy in non-small cell carcinoma. <b>1995</b> , 6 Suppl 1, 43-7; discussion 47-8		6
876	Is there a role for chemotherapy of non-small cell lung cancer?. <b>1995</b> , 6 Suppl 1, 79-82		3
875	Chemotherapy in non-small cell lung cancer. <b>1995</b> , 6 Suppl 1, 83-94; discussion 94-5		25
874	Induction or concomitant chemotherapy and radiotherapy for non-small-cell lung cancer: myth or reality. <b>1995</b> , 6 Suppl 3, S37-40		3
873	Chemotherapy of stage IIIB and IV non-small-cell lung cancer. <b>1995</b> , 6 Suppl 3, S41-4		14
872	Rapidly alternating combination of cisplatin-based chemotherapy and hyperfractionated accelerated radiotherapy in split course for stage IIIA and stage IIIB non-small cell lung cancer: results of a phase I-II study by the GOTHA group. Group d'Oncologie Thoracique des R�gions Alpes. <b>1995</b> , 31A, 342-8		5
871	European School of Oncology Advisory report to the Commission of the European Communities for the "Europe Against Cancer Programme" cost-effectiveness in cancer care. <b>1995</b> , 31A, 1410-24		27

870	Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer. <b>1995</b> , 60, 586-91; discussion 591-2	31
869	A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest. <b>1995</b> , 35, 304-12	6
868	Combined modality treatment for stage III non-small cell lung cancer. <b>1995</b> , 12 Suppl 2, S41-52	2
867	Radiotherapy alone for non-small cell lung carcinoma. Five-year disease-free survival and patterns of failure. <b>1995</b> , 34, 525-30	13
866	Non-small-cell lung carcinoma. Current and future therapeutic management. <b>1995</b> , 49, 362-75	6
865	Edatrexate studies in non-small cell lung cancer. <b>1995</b> , 12 Suppl 1, S187-91	3
864	Radiotherapy in non-small cell lung cancer: optimal doses and schedules. <b>1995</b> , 12 Suppl 1, S119-23	3
863	Pre-treatment prognostic factors in patients with stage III non-small cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy. <b>1995</b> , 13, 21-30	27
862	Neoadjuvant (induction) treatment for non-small cell lung cancer. <b>1995</b> , 12 Suppl 2, S33-40	14
861	Scheduling of chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. <b>1995</b> , 12 Suppl 2, S53-61	5
860	Impact of chemotherapy on survival in locally advanced non-small cell lung cancer: the Gustave-Roussy experience. <b>1995</b> , 12 Suppl 1, S79-85	2
859	Multimodality therapy in unresected stage III non-small cell lung cancer: the American Cooperative Groups' Experience. <b>1995</b> , 12 Suppl 1, S87-94	2
858	Future directions in non-small cell lung cancer. A personal view. <b>1995</b> , 12 Suppl 2, S147-52	9
857	Therapy of non-small cell lung cancer. <b>1995</b> , 12 Suppl 1, S133-45	4
856	New chemotherapy agents in the treatment of advanced non-small cell lung cancer: an update including data from the Seventh World Conference on Lung Cancer. <b>1995</b> , 12 Suppl 2, S63-99	16
855	Phase I study of vinorelbine and carboplatin in advanced non-small cell lung cancer. <b>1995</b> , 12, 247-57	10
854	Non-uniform dose/time fractionated radiation therapy and chemotherapy for non-small cell lung cancer. <b>1995</b> , 13, 57-67	1
853	Trials with mitomycin, ifosfamide and cisplatin in non-small cell lung cancer. <b>1995</b> , 12 Suppl 1, S95-106	8

852	Cancers bronchiques non ^ petites cellules stade III: perspectives de la radiochimioth�apie concomitante. <b>1995</b> , 82, 28-34	0
851	Effectiveness and toxicity of preoperative therapy in stage IIIA non-small cell lung cancer including the Memorial Sloan-Kettering experience with induction MVP in patients with bulky mediastinal lymph node metastases (Clinical N2). <b>1995</b> , 12 Suppl 1, S47-57	8
850	Therapeutic options for regionally advanced non-small cell lung cancer. <b>1996</b> , 14, 281-300	18
849	Cost analysis of hospital treatment--two chemotherapeutic regimens for non-surgical non-small cell lung cancer. GFPC (Groupe Fran�ais Pneumo Canc�ologie). <b>1996</b> , 14, 31-44	8
848	Phase II study of alternating doses of vinorelbine in combination with cisplatin for non-small cell lung cancer (NSCLC): a disappointing experience. <b>1996</b> , 16, 61-73	5
847	Hyperfractionated radiotherapy and concomitant cisplatin in stage III non-small cell lung cancer: a phase II study by the AIRO-Lombardia Cooperative Group. <b>1996</b> , 15, 85-91	4
846	A palliative accelerated irradiation regimen (PAIR) for advanced non-small-cell lung cancer (NSCLC). <b>1996</b> , 38, 195-203	8
845	Locally advanced non-small cell lung cancer: do we know the questions? A survey of randomized trials from 1966-1993. <b>1996</b> , 49, 183-92	20
844	Comparison of induction chemotherapy before radiotherapy with radiotherapy only in patients with locally advanced squamous cell carcinoma of the lung. The Swedish Lung Cancer Study Group. <b>1996</b> , 32A, 1893-900	35
843	Multimodality therapy in stage III non-small cell lung cancer. <b>1996</b> , 61, 1564-72	42
842	Pre-operative chemoradiotherapy in non-small cell lung cancer stage III patients. Feasibility, toxicity and long-term results of a phase II study. <b>1996</b> , 32A, 2064-9	18
841	Non-small cell lung cancer: an overview of diagnosis, staging, and treatment. <b>1996</b> , 12, 285-94	5
840	Radiation therapy for lung cancer. <b>1996</b> , 12, 304-11	1
839	A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study. <b>1996</b> , 14, 315-29	14
838	The economics of lung cancer management in Canada. <b>1996</b> , 14, 19-29	39
837	Recombinant human interferon-beta (rHuIFN-beta) and radiation therapy for inoperable non-small cell lung cancer. <b>1996</b> , 16, 891-902	12
836	Diagnosis and Treatment of Early-Stage Non-Small Cell Lung Cancer. <b>1996</b> , 1, 201-209	4
835	Lung cancer. <b>1996</b> , 35 Suppl 7, 46-53	2

834	Adjuvant and Induction Chemotherapies in Non-Small-Cell Lung Cancer. <b>1996</b> , 19, 221-225		
833	Treatment of cancer with radiation and drugs. <i>Journal of Clinical Oncology</i> , <b>1996</b> , 14, 3156-74	2.2	104
832	Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. <i>Journal of Clinical Oncology</i> , <b>1996</b> , 14, 1065-70	2.2	313
831	Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>1996</b> , 14, 1642-8	2.2	25
830	A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small-cell lung cancer. An EORTC Lung Cancer Cooperative Group trial. <b>1996</b> , 7, 139-44		24
829	Bias in the analysis and reporting of randomized controlled trials. <b>1996</b> , 12, 264-75		34
828	Impact of tumor extent and location on treatment outcome in patients with stage III non-small cell lung cancer treated with radiation therapy. <b>1996</b> , 26, 221-8		18
827	Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. <b>1996</b> , 125, 723-9		209
826	Do radiosensitizers enhance the treatment of patients with NSCLC? The need for better models and alternative methods of treatment. <b>1996</b> , 109, 115S-118S		3
825	Chest wall invasive non-small cell lung cancer: patterns of failure and implications for a revised staging system. <b>1996</b> , 3, 261-9		16
824	Promising new agents in the treatment of non-small cell lung cancer. <b>1996</b> , 37, 385-93		37
823	Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer. <b>1996</b> , 38, 561-5		3
822	The role of radiation therapy for stage IIIB non-small cell lung cancer: Impact of clinical nodal stage on survival. <b>1996</b> , 1, 13-17		3
821	A phase III randomized trial of cisplatin plus vindesine versus cisplatin plus vindesine plus mitomycin C versus cisplatin plus vindesine plus ifosfamide for advanced non-small-cell lung cancer. <b>1996</b> , 1, 49-54		11
820	Predicting distant failure in nasopharyngeal cancer. <b>1996</b> , 106, 765-71		13
819	Combined chemotherapy and radiation therapy in surgically unresectable regionally advanced non-small cell lung cancer. <b>1996</b> , 6, 86-91		10
818	Perioperative therapy for locoregional nonsmall-cell lung cancer. <b>1996</b> , 62, 65-74		
817	Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935. <b>1996</b> , 77, 2393-9		51

816	Adoptive immunotherapy for nonsmall cell lung carcinoma. A fourth treatment modality, complicated radiation sensitizer, or none of the above. <b>1996</b> , 78, 195-8	1
815	A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. <b>1996</b> , 78, 244-51	81
814	Chemoradiation enhances response in stage IIIB lung cancer. <b>1996</b> , 4, 171-175	
813	Activation of lavage lymphocytes in lung injuries caused by radiotherapy for lung cancer. <b>1996</b> , 34, 459-67	47
812	Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study. <b>1996</b> , 35, 343-50	25
811	Stage-directed treatment guidelines. <b>1996</b> , 20, 157-78	0
810	Locally advanced non-small cell lung cancer: the "local" issue. <b>1996</b> , 20, 197-212	
809	High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: unusual toxicity and promising early results. <b>1996</b> , 36, 593-9	49
808	It's about time, or is it volume, fractionation, or technique?. <b>1996</b> , 36, 753-5	2
807	Concurrent cisplatin-vindesine and hyperfractionated thoracic radiotherapy in locally advanced nonsmall cell lung cancer. <b>1996</b> , 35, 519-525	12
806	Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis. <b>1996</b> , 14, 115-30	31
805	Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents. <b>1996</b> , 14, 161-7	55
804	Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. <b>1996</b> , 2, 985-91	615
803	Results of a trial with topotecan dose escalation and concurrent thoracic radiation therapy for locally advanced, inoperable nonsmall cell lung cancer. <b>1996</b> , 36, 1215-20	28
802	Improving treatment planning accuracy through multimodality imaging. <b>1996</b> , 35, 117-24	34
801	Combined-modality therapy for unresectable, stage III non-small-cell lung cancer--caveat emptor or caveat venditor?. <b>1996</b> , 88, 1175-7	7
800	Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. <b>1996</b> , 88, 1210-5	783
799	More power to trials for non-small-cell lung cancer. <b>1996</b> , 7, 119-20	1

798	The role of induction (neoadjuvant) chemotherapy in stage IIIA NSCLC. <b>1996</b> , 109, 102S-106S	35
797	Cis/carboplatin + vinorelbine +/- radiotherapy in stage III and IV non small cell lung carcinoma. <b>1997</b> , 9, 62-5	
796	Argumentos a favor da prescriç de Quimioterapia Citostática (Qt) no Carcinoma Pulmonar de células Pequenas (CPNPC)**Texto em parte apresentado no XII Congresso de Pneumologia (Porto, 11 a 13 de Novembro de 1996).. <b>1997</b> , 3, 265-282	2
795	Non-small cell lung cancer: novel treatment strategies. <b>1997</b> , 112, 266S-268S	3
794	Intensity of neoadjuvant therapy in resectable non-small cell lung cancer. <b>1997</b> , 17 Suppl 1, S111-9	2
793	The multimodality treatment of stage III A/B non-small cell lung cancer. The role of surgery, radiation, and chemotherapy. <b>1997</b> , 11, 279-301	7
792	Continuous hyperfractionated accelerated therapy in non-small-cell lung cancer. <b>1997</b> , 350, 888	
791	Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. <b>1997</b> , 44, 17-22	182
790	Hyperfractionation: where do we stand?. <b>1997</b> , 43, 1-21	50
789	Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). <b>1997</b> , 17, 147-61	77
788	Non-small cell lung cancer: an overview of current management. <b>1997</b> , 33 Suppl 1, S2-7	23
787	[Concomitant radiochemotherapy with cisplatin-etoposide with or without surgery in stage III non-small cell lung cancers: results of a pilot study in 67 patients]. <b>1997</b> , 1, 292-9	0
786	[Concomitant radiochemotherapy for locally advanced bronchial cancers: current results and prospects]. <b>1997</b> , 1, 113-20	0
785	[Induction chemotherapy followed by concomitant combined radiotherapy and chemotherapy in stage III non-small cell bronchial carcinoma]. <b>1997</b> , 1, 121-31	1
784	[Concomitant radiochemotherapy in inoperable non-small cell lung cancer]. <b>1997</b> , 1, 143-7	0
783	[A combined radiochemotherapy trial for non-small cell lung cancers: initial results]. <b>1997</b> , 1, 170-3	0
782	[Biological basis of combined chemo-radiotherapy. Applications to lung cancers]. <b>1997</b> , 1, 29-41	3
781	Pancoast (superior sulcus) tumors. <b>1997</b> , 63, 1810-8	69



780	Carboplatin as radiosensitizer in non-small cell lung cancer after cisplatin containing chemotherapy. A phase I study of a groupe francais de pneumo-cancerologie (G.F.P.C.). <b>1997</b> , 18, 71-81		3
779	The benefits of combination chemotherapy for stage III and IV non-small cell lung cancer. <b>1997</b> , 18, 134		
778	Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study. <i>Journal of Clinical Oncology</i> , <b>1997</b> , 15, 1409-17	2.2	21
777	Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , <b>1997</b> , 15, 2996-3018	2.2	491
776	Lung cancer cure, care, and cost: let the data be your guide. <i>Journal of Clinical Oncology</i> , <b>1997</b> , 15, 3027-2.2		1
775	Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>1997</b> , 15, 330-40	2.2	107
774	3. Radiation therapy. <b>1997</b> , 166, S11		1
773	The Role of Multimodality Therapy in Locoregional Non-small Cell Lung Cancer. <b>1997</b> , 6, 769-791		20
772	Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial. <i>Journal of Clinical Oncology</i> , <b>1997</b> , 15, 2850-7	2.2	61
771	Cost of combined modality interventions for stage III non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>1997</b> , 15, 3038-48	2.2	47
770	The Use of Docetaxel in Non-Small Cell Lung Cancer. <b>1997</b> , 29, 106-116		1
769	Postoperative and Preoperative Chemotherapy for Non-Small Cell Lung Cancer. <b>1997</b> , 4, 297-306		5
768	The Emerging Role of Paclitaxel and Carboplatin in Non-Small Cell Lung Carcinoma. <b>1997</b> , 29, 73-90		1
767	Treatment of Stage IV Non-Small Cell Lung Cancer. <b>1997</b> , 29, 56-72		1
766	Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group. <b>1997</b> , 39, 537-44		113
765	[Lung cancer--hopelessness in inoperability? A 10-year follow-up]. <b>1997</b> , 173, 352-61		
764	[CHARTWEL-Bronchus (ARO 97-1): a randomized multicenter trial to compare conventional fractionated radiotherapy with CHARTWEL radiotherapy in inoperable non-small-call bronchial carcinoma]. <b>1997</b> , 173, 663-7		22
763	[Improved survival through simultaneous radiochemotherapy versus radiotherapy alone in stage III of non-small-cell bronchial carcinoma]. <b>1997</b> , 173, 239-40		0

762	What a surgeon needs to know about radiation. <b>1997</b> , 4, 516-22	2
761	Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study. <b>1997</b> , 41, 75-8	19
760	Phase I-II trial of concomitant continuous carboplatin (CBDCA) infusion and radiotherapy in advanced nonsmall cell lung cancer with evaluation for surgery: final report. <b>1997</b> , 37, 93-101	2
759	Concurrent daily carboplatin and accelerated hyperfractionated thoracic radiotherapy in locally advanced nonsmall cell lung cancer. <b>1997</b> , 37, 103-9	11
758	Concurrent carboplatin, etoposide and thoracic radiation for poor-risk stage III non-small-cell lung carcinoma: a pilot study. <b>1997</b> , 38, 157-61	9
757	Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04. <b>1997</b> , 38, 149-55	87
756	A phase II trial of radiochemotherapy with daily carboplatin, after induction chemotherapy (carboplatin and etoposide), in locally advanced nonsmall-cell lung cancer: final analysis. <b>1997</b> , 38, 163-8	9
755	Stage III nonsmall cell lung cancer: still a challenge for the radiation oncologist. <b>1997</b> , 39, 533-5	2
754	Non-surgical therapy for patients with advanced non-small cell lung cancer. <b>1998</b> , 3, 175-82	
753	Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer [seecomments]. <b>1998</b> , 78, 257-62	39
752	Spinal cord localization in the treatment of lung cancer: use of radiographic landmarks. <b>1998</b> , 40, 347-51	4
751	Staging and surgery for non-small cell lung cancer (NSCLC). <b>1998</b> , 7, 25-43	9
750	The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma. <b>1998</b> , 82, 1037-1048	44
749	Chemotherapeutic options in lung cancer. <b>1998</b> , 83, 1740-1750	3
748	Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. <b>1998</b> , 17, 2815-34	3600
747	Brachytherapy in lung cancer. <b>1998</b> , 67, 60-70	32
746	[Treatment of stage IIIB loco-regionally advanced non-small-cell bronchial carcinomas with radiation and interferon-beta. Preliminary results of a phase II study]. <b>1998</b> , 174, 300-5	0
745	Treatment of advanced (stages III and IV) non-small-cell lung cancer. <b>1998</b> , 22, 85-132	7

744	Image registration: an essential part of radiation therapy treatment planning. <b>1998</b> , 40, 197-205	76
743	A phase I study of daily carboplatin and simultaneous accelerated, hyperfractionated chest irradiation in patients with regionally inoperable non-small cell lung cancer. <b>1998</b> , 40, 559-67	12
742	Is the chest radiograph a reliable tool in the assessment of tumor response after radiotherapy in nonsmall cell lung carcinoma?. <b>1998</b> , 41, 1037-45	13
741	Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1547 patients on four radiation therapy oncology group (RTOG) studies in inoperable nonsmall-cell lung cancer (NSCLC). <b>1998</b> , 42, 263-7	59
740	A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small-cell lung cancer: a 5-year follow-up report. <b>1998</b> , 42, 479-86	24
739	Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. <b>1998</b> , 42, 469-78	184
738	A phase II study of cisplatin, oral administration of etoposide, OK-432 and radiation therapy for inoperable stage III non-small cell lung cancer. <b>1998</b> , 3, 365-369	
737	[Treatment of inoperable non-small cell lung cancer: induction chemotherapy or hyperfractionated radiotherapy? Apropos of 2 recent therapeutic trials]. <b>1998</b> , 2, 287-9	0
736	[Which fractionation and radiation dose for non-small-cell bronchial cancers?]. <b>1998</b> , 2, 574-8	
735	Chemoradiation for malignant epithelial tumors. <b>1998</b> , 2, 7-11	7
734	Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial. <b>1998</b> , 34, 838-44	59
733	Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study Group. <b>1998</b> , 34, 1036-44	110
732	The relevance of transforming growth factor beta 1 in pulmonary injury after radiation therapy. <b>1998</b> , 19, 109-20	52
731	A phase II trial, feasibility of combination of daily cisplatin and accelerated radiotherapy via concomitant boost in stage III non-small cell lung cancer. <b>1998</b> , 20, 37-46	4
730	Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study. <b>1998</b> , 21, 203-11	27
729	Sequential treatment with vindesine-ifosfamide-platinum (VIP) chemotherapy followed by platinum sensitized radiotherapy in stage IIIB non-small cell lung cancer: a phase II trial. <b>1998</b> , 22, 45-53	7
728	Induction chemoradiotherapy for advanced stage III non-small cell lung cancer: long-term follow-up in 42 patients. <b>1998</b> , 22, 127-37	18
727	Non-surgical therapy for the patients with advanced non-small cell lung cancer. <b>1998</b> , 3, 159-66	1

726	Clinical studies in non-small cell lung cancer: the CALGB experience. <b>1998</b> , 16, 72-9		11
725	Management of lung cancer. <b>1998</b> , 7, 170-7		1
724	The current state of the art in treating stage IIIA (N2) lung cancer. <b>1998</b> , 9, 243-5		1
723	Combined-modality treatment of locally advanced non-small cell lung cancer: incorporation of novel chemotherapeutic agents. <b>1998</b> , 113, 53S-60S		23
722	Long-Lasting Response to Vinorelbine in Unresectable Non-Small Cell Lung Carcinoma: A Case With Concomitant Good Quality of Life. <b>1998</b> , 316, 398-400		
721	Using a treatment-tradeoff method to elicit preferences for the treatment of locally advanced non-small-cell lung cancer. <b>1998</b> , 18, 256-67		43
720	Chemotherapy for non-small cell lung cancer: the experience of the Lung Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. <b>1998</b> , 113, 28S-31S		19
719	Concurrent Radiochemotherapy with Ifosfamide in Unresectable Stage III Non-Small-Cell Lung Cancer. <b>1998</b> , 21, 57-62		1
718	Considerations in optimizing radiation therapy for non-small cell lung cancer. <b>1998</b> , 113, 46S-52S		7
717	Perceptions of prognosis, treatment, and treatment impact on prognosis in non-small cell lung cancer. <b>1998</b> , 114, 593-604		31
716	Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>1998</b> , 16, 3078-81	2.2	43
715	Altered Fractionation Radiotherapy in Lung Cancer. <b>1998</b> , 84, 171-175		
714	Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>1998</b> , 16, 635-41	2.2	34
713	Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. <i>Journal of Clinical Oncology</i> , <b>1998</b> , 16, 622-34	2.2	285
712	Phase I study of docetaxel with concomitant thoracic radiation therapy. <i>Journal of Clinical Oncology</i> , <b>1998</b> , 16, 159-64	2.2	139
711	Experience with new chemotherapeutic agents in non-small cell lung cancer. <b>1998</b> , 113, 32S-39S		16
710	Combined Modality Treatment of Locally Advanced Lung Cancer. <b>1998</b> , 84, 259-269		2
709	The Use of Erythropoietin in Radiation Oncology. <b>1998</b> , 5, 33-40		8

708	New chemotherapeutic agents in the treatment of non-small cell lung cancer: the Australian experience. <b>1998</b> , 113, 24S-27S		2
707	Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 3512-21	2.2	160
706	Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 2692-9	2.2	1233
705	The rationale and use of three-dimensional radiation treatment planning for lung cancer. <b>1999</b> , 116, 539S-545S		9
704	Adjuvant chemotherapy and radiation therapy for elimination of residual microscopic non-small cell lung cancer. <b>1999</b> , 14, 347-51		
703	Combined modality therapy of non-small cell lung cancers. <b>1999</b> , 10, S93-S98		8
702	Induction chemotherapy followed by concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer. <b>1999</b> , 38, 1005-9		9
701	Paclitaxel-based therapy in non-small-cell lung cancer: improved third generation chemotherapy. <b>1999</b> , 10 Suppl 5, S63-7		5
700	Risk factors for severe radiation pneumonitis in lung cancer. <b>1999</b> , 29, 192-7		47
699	Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer. Thoracic Oncology Program. <b>1999</b> , 10 Suppl 5, S35-40		3
698	Palliative radiation therapy. <b>1999</b> , 2, 87-97		20
697	Lung cancer radiation treatment in the elderly. <b>1999</b> , 32, 45-8		3
696	Setup reproducibility in radiation therapy for lung cancer: a comparison between T-bar and expanded foam immobilization devices. <b>1999</b> , 43, 211-6		47
695	ACR appropriateness criteria. Expert Panel on Radiation Oncology. American College of Radiology. <b>1999</b> , 43, 125-68		9
694	Dose escalation of chest in non-small cell lung cancer: is three-dimensional conformal radiation therapy really necessary?. <b>1999</b> , 45, 339-50		26
693	Is prolonged survival possible for patients with supraclavicular node metastases in non-small cell lung cancer treated with chemoradiotherapy?: Analysis of the Radiation Therapy Oncology Group experience. <b>1999</b> , 44, 847-53		20
692	Effectiveness of accelerated radiotherapy for patients with inoperable non-small cell lung cancer (NSCLC) and borderline prognostic factors without distant metastasis: a retrospective review. <b>1999</b> , 44, 1053-6		34
691	Clinical and dosimetric predictors of radiation-induced esophageal toxicity. <b>1999</b> , 45, 97-103		154

690	Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer. <b>1999</b> , 79, 1462-7	38
689	Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma. <b>1999</b> , 80, 1792-6	46
688	Role of chemotherapy against micrometastatic cancer. <b>1999</b> , 18, 151-72	1
687	Guideline Document. <b>1999</b> , 11, S1-S53	13
686	The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer. <b>1999</b> , 117, 744-50	51
685	Alternating chemotherapy and accelerated split-course irradiation in locally advanced nonsmall cell lung carcinoma. <b>1999</b> , 85, 2144-50	3
684	A phase I/II trial of neoadjuvant chemotherapy with cisplatin and vinorelbine followed by accelerated irradiation for patients with inoperable nonsmall cell lung carcinoma. <b>1999</b> , 85, 2562-2569	11
683	Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. <b>1999</b> , 86, 1867-76	203
682	Results of a phase II concurrent chemoradiotherapy study using three-dimensional conformal radiotherapy with cisplatin and oral etoposide in stage III nonsmall-cell lung cancer. <b>1999</b> , 7, 49-53	16
681	Prevention of irradiation-induced esophagitis by plasmid/liposome delivery of the human manganese superoxide dismutase transgene. <b>1999</b> , 7, 204-17	71
680	Treatment outcome for patients with primary nonsmall-cell lung cancer and synchronous brain metastasis. <b>1999</b> , 7, 313-9	57
679	Management of Advanced Non-Small Cell Lung Cancer. <b>1999</b> , 5, 167-179	
678	[Non-metastatic advanced non-small cell lung carcinoma: systemic high-dose brachytherapy following curative external radiotherapy]. <b>1999</b> , 3, 468-74	4
677	Highlights from the Second Cuneo Lung Cancer Conference. <b>1999</b> , 23, 77-90	1
676	Chemoradiation for inoperable non small cell lung cancer: a phase II study using a regimen with acceptable toxicity. <b>1999</b> , 23, 233-40	0
675	Summary of the proceedings of the United States--Japan lung cancer clinical trials summit: San Francisco, CA, 20-22 November, 1998. <b>1999</b> , 24, 181-91	2
674	Preoperative chemoradiotherapy and surgery for selected non-small cell lung cancer IIIB subgroups: long-term results. <b>1999</b> , 68, 1144-9	69
673	A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. <b>1999</b> , 52, 129-36	122

672	The changing role of surgery in the diagnosis and treatment of cancer. <b>1999</b> , 106, 81-9		2
671	A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. European Lung Cancer Working Party. <b>1999</b> , 10, 295-303		19
670	Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 4-11	2.2	197
669	Role of chemotherapy in stages I to III non-small cell lung cancer. <b>1999</b> , 116, 509S-516S		10
668	Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 2981-9	2.2	407
667	Locally advanced, unresectable non-small cell lung cancer: new treatment strategies. <b>2000</b> , 117, 123S-126S		24
666	Combined modality therapy for unresectable stage III non-small cell lung cancer: new chemotherapy combinations. <b>2000</b> , 117, 127S-132S		12
665	The problem of performing adequately sized randomized trials to demonstrate small survival benefits. <b>2000</b> , 15, 819-20		
664	Sequential re-analysis of a phase-III clinical trial in non-small cell lung cancer. <b>2000</b> , 15, 821-7		4
663	Fluorine-18 FDG dual-head gamma camera coincidence imaging of radiation pneumonitis. <b>2000</b> , 25, 866-9		23
662	Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: long-term follow-up results. Japan Clinical Oncology Group Protocol 8902. <b>2000</b> , 11, 445-50		16
661	Results of a dose-intense phase 1 study of a combination chemotherapy regimen with cisplatin and epidoxorubicin including medroxyprogesterone acetate and recombinant interleukin-2 in patients with inoperable primary lung cancer. <b>2000</b> , 23, 267-74		11
660	Patterns of practice survey for nonsmall cell lung carcinoma in the U.S. <b>2000</b> , 88, 1336-46		31
659	Role of multimodality treatment for lung cancer. <b>2000</b> , 18, 143-51		18
658	Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable Stage IIIA/B nonsmall cell lung carcinoma. <b>2000</b> , 89, 534-542		34
657	Combining taxanes with radiation for solid tumors. <b>2000</b> , 90, 113-127		17
656	A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). <b>2000</b> , 47, 931-7		69
655	Concomitant boost radiation therapy for inoperable non-small-cell lung cancer: preliminary report of a prospective randomized study. <b>2000</b> , 47, 413-8		20

654	Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. <b>2000</b> , 48, 89-94		208
653	Involved-field radiotherapy alone for early-stage non-small-cell lung cancer. <b>2000</b> , 48, 703-10		84
652	Characteristics of 49 patients who survived for 5 years following radical radiation therapy for non-small cell lung cancer: the potential for cure. <b>2000</b> , 46, 63-9		16
651	Letter to the Editor. <i>Clinical Lung Cancer</i> , <b>2000</b> , 2, 152	4.9	1
650	The physical parameters and molecular events associated with radiation-induced lung toxicity. <b>2000</b> , 10, 296-307		103
649	Non-small cell lung cancer. Introduction. <b>2000</b> , 10, 263-6		3
648	Radiation and chemotherapy for patients with stage III non-small cell lung cancer. <b>2000</b> , 10, 289-95		9
647	Multimodality treatment of resectable non small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2000</b> , 1, 194-200; discussion 201	4.9	3
646	Manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) gene therapy protection of the esophagus from chemoradiotherapy damage during treatment of locally unresectable non-small-cell lung cancer (NSCLC). <i>Clinical Lung Cancer</i> , <b>2000</b> , 1, 302-4	4.9	7
645	A phase I trial of outpatient weekly docetaxel and concurrent radiation therapy for stage III unresectable non small-cell lung cancer: a Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial. <i>Clinical Lung Cancer</i> , <b>2000</b> , 1 Suppl 1, S27-31	4.9	10
644	Gemcitabine plus radiation therapy in the treatment of locally advanced non small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2000</b> , 2 Suppl 1, S33-8	4.9	
643	Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team. <b>2000</b> , 119, 429-39		199
642	Postoperative radiotherapy in resected non-small-cell lung cancer: every creek has two banks. <b>2000</b> , 2, 51-3		
641	The role of induction therapy in the management of resectable non-small cell lung cancer. <b>2000</b> , 7, 45-55		6
640	Innovative treatment strategies in locally advanced and/or unresectable non-small cell lung cancer. <b>2000</b> , 7, 25-34		7
639	Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 131-5	2.2	118
638	Target Volume Definition and Locoregional Failure in Non-Small-Cell Lung Cancer. <b>2000</b> , 34, 89-96		1
637	Modified Fractionation in the Radical Treatment of Non-Small-Cell Lung Cancer. <b>2000</b> , 34, 80-88		3



636	Phase II trial of daily low-dose carboplatin and thoracic radiotherapy in elderly patients with locally advanced non-small cell lung cancer. <b>2000</b> , 30, 59-64		31
635	Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer. <b>2000</b> , 39, 225-9		16
634	Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. <b>2000</b> , 117, 358-64		522
633	Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. <b>2000</b> , 70, 1826-31	200	
632	Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: a phase I study. <b>2000</b> , 29, 131-7		21
631	Prognostic impact of bulky mediastinal lymph nodes (N2>2.5 cm) in patients with locally advanced non-small-cell lung cancer (LA-NSCLC) treated with platinum-based induction chemotherapy. <b>2000</b> , 30, 107-16		9
630	A preoperative alternating chemotherapy and radiotherapy program for patients with stage IIIA (N2) non-small cell lung cancer. <b>2000</b> , 29, 49-56		3
629	Radiotherapy for non-small cell lung cancer in patients aged 75 and over: safety, effectiveness and possible impact on survival. <b>2000</b> , 28, 43-50		29
628	Chemotherapy for non-small cell lung cancer. <b>2000</b> , CD002139		28
627	Pilot and safety trial of carboplatin, paclitaxel, and thalidomide in advanced non small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2000</b> , 2, 48-52; discussion 53-4	4.9	22
626	The impact of three-dimensional radiation on the treatment of non-small cell lung cancer. <b>2000</b> , 56, 157-67		47
625	Topoisomerase I inhibitors in the combined modality therapy of lung cancer. <i>Clinical Lung Cancer</i> , <b>2001</b> , 2 Suppl 2, S34-40	4.9	4
624	Endoscopic findings of radiation esophagitis in concurrent chemoradiotherapy for intrathoracic malignancies. <b>2001</b> , 58, 273-8		36
623	Predictive factors in radiotherapy for non-small cell lung cancer: present status. <b>2001</b> , 31, 43-56		81
622	Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. <b>2001</b> , 31, 257-65		18
621	Carboplatin and vinorelbine in untreated locally advanced and metastatic non-small cell lung cancer. <b>2001</b> , 32, 173-8		7
620	A Phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer. <b>2001</b> , 32, 281-7		24
619	Treatment and survival of patients with non-small cell lung cancer Stage IIIA diagnosed in 1989-1994: a study in the region of the Comprehensive Cancer Centre East, The Netherlands. <b>2001</b> , 34, 19-27		3

618	Vinorelbine, ifosfamide and cisplatin as first-line treatment in patients with inoperable non-small cell lung cancer. <b>2001</b> , 34, 305-11		9
617	Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial. <b>2001</b> , 34, 441-9		23
616	Trends and perspectives in multimodality therapy of locoregionally advanced non-small cell lung cancer. <b>2001</b> , 33 Suppl 1, S85-9		
615	Development of treatment strategies in locally advanced non-small cell lung cancer (take home messages). <b>2001</b> , 33 Suppl 1, S91-7		
614	Chemotherapy in Stage I/II NSCLC and projects of the EORTC-Lung Cancer Group for Early Stage Lung Cancer. <b>2001</b> , 34 Suppl 3, S53-8		4
613	The role of chemotherapy in early non-small-cell lung cancer management. <b>2001</b> , 34 Suppl 3, S63-74		22
612	Radiosensitization with chemotherapeutic agents. <b>2001</b> , 34 Suppl 4, S81-90		46
611	Combined chemotherapy and radiation in locally advanced non-small-cell lung cancer. <b>2001</b> , 2, 335-42		34
610	Programming of radiotherapy in the treatment of non-small-cell lung cancer--a way to advance care. <b>2001</b> , 2, 401-8		5
609	Cinquième Journé de cancérologie Jean Papillon. Les cancers bronchiques non petites cellules, Lyon, 24 Juin 2000. <b>2001</b> , 5, 35-81		
608	[Estimation of the probability of mediastinal involvement: a statistical definition of the clinical target volume for 3-dimensional conformal radiotherapy in non-small-cell lung cancer?]. <b>2001</b> , 5, 725-36		11
607	The role of radiotherapy and the value of combined treatment in lung cancer. <b>2001</b> , 37 Suppl 7, S91-8		2
606	Cáncer de pulmón no microcálico. <b>2001</b> , 8, 2985-2995		
605	Innovative treatments for non-small cell lung cancer. <b>2001</b> , 10, 1021-32		2
604	Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 1344-9	2.2	134
603	The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer. <b>2001</b> , 12, 1671-5		69
602	Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 3758-65	2.2	67
601	Current standards of care in small-cell and non-small-cell lung cancer. <b>2001</b> , 61 Suppl 1, 3-13		119

600 Locally advanced non-small cell lung cancer. **2001**, 2, 27-42

599 Recent developments in weekly paclitaxel therapy in lung cancer. **2001**, 3, 165-9

3

598 Expression of BCRP gene in the normal lung tissue and lung cancer. **2001**, 13, 22-26

597 Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis. **2001**, 49, 649-55

139

596 Impact of neoadjuvant chemotherapy on Ki-67 and PCNA labeling indices for esophageal squamous cell carcinomas. **2001**, 49, 527-32

6

595 Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial. **2001**, 50, 19-25

46

594 Dosimetric predictors of radiation esophagitis in patients treated for non-small-cell lung cancer with carboplatin/paclitaxel/radiotherapy. **2001**, 51, 291-5

58

593 Taxanes in combined modality therapy for solid tumors. **2001**, 37, 237-47

58

592 F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. **2001**, 92, 886-95

195

591 Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial. **2001**, 92, 1213-23

151

590 UFT plus oral leucovorin calcium (Orzel) and radiation in combined modality therapy: a comprehensive review. **2001**, 96, 1-10

12

589 Tissue/dose compensation to reduce toxicity from combined radiation and chemotherapy for advanced head and neck cancers. **2001**, 96 Suppl, 61-70

26

588 Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer. **2001**, 51, 915-22

173

587 Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer. **2001**, 29, 22-27

2

586 Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer. **2001**, 122, 796-802

107

585 Commentary on Effectiveness of Radiation Therapy on Non-Small-Cell Lung Cancer—*Clinical Lung Cancer*, **2001**, 2, 191-192

4.9 1

584 Commentary on Induction and Concurrent Paclitaxel/Carboplatin Every 3 Weeks with Thoracic Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: An Interim Report—*Clinical Lung Cancer*, **2001**, 3, 133

4.9

583 Effectiveness of radiation therapy on non-small-cell lung cancer. *Clinical Lung Cancer*, **2001**, 2, 182-90; discussion 191-4

4.9 3

582	Induction and concurrent paclitaxel/carboplatin every 3 weeks with thoracic radiotherapy in locally advanced non-small-cell lung cancer: an interim report. <i>Clinical Lung Cancer</i> , <b>2001</b> , 3, 125-32; discussion 133	4.9	6
581	Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. <b>2001</b> , 16, 932-8		100
580	A novel therapeutic strategy against monocytic leukemia with deoxyadenosine analogs and adenosine deaminase inhibitors. <b>2001</b> , 42, 953-62		11
579	Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium. <b>2001</b> , 6 Suppl 1, 20-4		12
578	Induction chemotherapy followed by concomitant chemoradiotherapy for non-small cell lung cancer. <b>2001</b> , 6 Suppl 1, 25-7		9
577	Oncodiagnosis panel: 1999. Cancer of the lung: oncodiagnosis. <b>2001</b> , 21, 1573-96		4
576	Lung Cancer. <b>2002</b> ,		
575	Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. <b>2002</b> , 87, 258-63		22
574	Platinum drugs in the treatment of non-small-cell lung cancer. <b>2002</b> , 87, 825-33		75
573	[Recommendations on the therapy of bronchial carcinoma]. <b>2002</b> , 56, 113-31		25
572	Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer. <b>2002</b> , 20, 686-92		10
571	Phase II neoadjuvant trial of paclitaxel by 96-hour continuous infusion (CIVI) in combination with cisplatin followed by chest radiotherapy for patients with stage III non-small-cell lung cancer. <b>2002</b> , 25, 269-73		4
570	A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer. <b>2002</b> , 25, 238-43		39
569	Subsets more likely to benefit from surgery or prophylactic cranial irradiation after chemoradiation for localized non-small-cell lung cancer. <b>2002</b> , 25, 583-7		25
568	Teraptica do carcinoma pulmonar n de pequenas celulas. <b>2002</b> , 8, 237-259		4
567	The treatment of unresectable, locally advanced non-small-cell lung cancer: a radiation therapy perspective with an emphasis on the trials of the Radiation Therapy Oncology Group. <i>Clinical Lung Cancer</i> , <b>2002</b> , 3, 191-9	4.9	
566	A phase II study of continuous concurrent thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer. <b>2002</b> , 36, 105-11		8
565	Accelerated hyperfractionated radiation, concurrent paclitaxel/cisplatin chemotherapy and surgery for stage III non-small cell lung cancer. <b>2002</b> , 36, 167-74		7

564	Treatment of brain metastases in patients with non-small cell lung cancer (NSCLC) by stereotactic linac-based radiosurgery: prognostic factors. <b>2002</b> , 37, 87-94		50
563	Carboplatin plus paclitaxel and sequential radiation followed by consolidation carboplatin and paclitaxel in patients with previously untreated locally advanced NSCLC. A Hoosier Oncology Group (HOG) phase II study. <b>2002</b> , 38, 85-9		6
562	Consensus development conference on the medical treatment of non-small cell lung cancer: treatment of the early stages. <b>2002</b> , 38 Suppl 3, S23-9		59
561	Gemcitabine (Gemzar)-based induction chemotherapy in non-small-cell lung cancer. <b>2002</b> , 38 Suppl 2, S13-9		5
560	Targeted therapy in non-small cell lung cancer. <b>2002</b> , 38 Suppl 2, S29-32		19
559	[Locally advanced non-small-cell bronchial cancer: role of exclusive chemoradiotherapy]. <b>2002</b> , 6 Suppl 1, 117s-124s		0
558	Use of chemo-radiotherapy in locally advanced non-small cell lung cancer. <b>2002</b> , 38, 292-9		7
557	Building a better therapy for stage IIIA non-small cell lung cancer. <i>Clinics in Chest Medicine</i> , <b>2002</b> , 23, 191-207	5.3	
556	Therapy for stage IIIB and stage IV non-small cell lung cancer. <i>Clinics in Chest Medicine</i> , <b>2002</b> , 23, 209-24	5.3	2
555	Recent advances and dilemmas in the radiotherapeutic management of locally advanced non-small cell lung cancer. <b>2003</b> , 75, 489-505		
554	Outcomes and cost-effectiveness of alternative staging strategies for non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 263-73	2.2	12
553	[Role of radiotherapy in non-small cell lung cancer]. <b>2002</b> , 91, 1307-14		
552	Radiotherapy versus chemotherapy plus radiotherapy in surgically treated IIIA N2 non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2002</b> , 4, 95-103	4.9	12
551	Docetaxel/radiation combinations: rationale and preclinical findings. <i>Clinical Lung Cancer</i> , <b>2002</b> , 3 Suppl 2, S29-36	4.9	13
550	Gemcitabine induction chemotherapy in non-small cell lung cancer. <b>2002</b> , 29, 55-60		8
549	Exploring the role of the radioprotector amifostine in locally advanced non-small cell lung cancer: Radiation Therapy Oncology Group trial 98-01. <b>2002</b> , 12, 40-5		34
548	Concurrent paclitaxel-cisplatin and twice-a-day irradiation in stage IIIA and IIIB NSCLC shows improvement in local control and survival with acceptable hematologic toxicity. <b>2002</b> , 8, 163-9		4
547	Entwicklungen in der primären Strahlentherapie und Radiochemotherapie beim nichtklein-zelligen Bronchialkarzinom. <b>2002</b> , 8, 448-461		3

546	Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. <b>2002</b> , 52, 49-57	180
545	Impact of institutional experience on survival outcome of patients undergoing combined chemoradiation therapy for inoperable non-small-cell lung cancer. <b>2002</b> , 52, 362-70	15
544	Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center. <b>2002</b> , 52, 351-61	66
543	In regard to Sim et al., <i>IJROBP</i> 2001;51:660-665. <b>2002</b> , 53, 512-3; author reply 513	
542	Comorbidity and Karnofsky performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. <b>2002</b> , 54, 357-64	159
541	Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in Stage III non-small-cell lung cancer. <b>2002</b> , 52, 75-80	39
540	A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04). <b>2002</b> , 52, 1173-9	46
539	High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. <b>2002</b> , 54, 348-56	176
538	Fatal pulmonary fibrosis associated with induction chemotherapy with carboplatin and vinorelbine followed by CHART radiotherapy for locally advanced non-small cell lung cancer. <b>2002</b> , 14, 361-6	24
537	Dose-escalation with CHARTWEL (continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer. <b>2002</b> , 14, 352-60	22
536	Sequential chemoradiotherapy versus radiotherapy in the management of locally advanced non-small-cell lung cancer. <b>2003</b> , 20, 14-9	8
535	A long-term survivor of complete resection for stage IIB adenocarcinoma of the lung and chemoradiotherapy for postoperative metastasis to the abdominal rectus muscle. <b>2003</b> , 51, 256-8	3
534	The management of the patient undergoing combined modality therapy for locally advanced non-small cell lung cancer. <b>2003</b> , 4, 45-53	3
533	Management of patients with non-small cell lung cancer and poor performance status. <b>2003</b> , 4, 55-9	8
532	Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results. <b>2003</b> , 179, 823-31	21
531	Preliminary results of radiotherapy with or without weekly paclitaxel in locally advanced non-small cell lung cancer. <b>2003</b> , 129, 52-6	13
530	Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer. <b>2003</b> , 30, 2-9	27
529	Induction therapy for early-stage lung cancer? The rationale behind the question. <i>Clinical Lung Cancer</i> , <b>2003</b> , 4, 304-6	4-9

528	Chemoradiotherapy: emerging treatment improvement strategies. <b>2003</b> , 25, 152-67	81
527	Adenine analogs as potential differentiation therapy agents for acute myeloid leukemia. <b>2003</b> , 59, 14-22	5
526	Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. <b>2003</b> , 56, 988-95	79
525	Three-dimensional conformal radiotherapy in the radical treatment of non-small cell lung cancer. <b>2003</b> , 15, 412-9	
524	Chemotherapy in metastatic and locally advanced non-small cell lung cancer. <b>2003</b> , 21, 98-110	10
523	Induction chemotherapy followed by radical local therapy for locally advanced non-small cell lung cancer. <b>2003</b> , 21, 111-21	4
522	Complex and controversial issues in locally advanced non-small cell lung carcinoma. <b>2003</b> , 21, 128-37	11
521	Translational research in lung cancer. <b>2003</b> , 21, 205-19	13
520	Phase I/II study of daily carboplatin, 5-fluorouracil and concurrent radiation therapy for locally advanced non-small-cell lung cancer. <b>2003</b> , 89, 803-7	11
519	Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. <b>2003</b> , 55, 337-41	156
518	Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer. <b>2003</b> , 56, 996-1004	21
517	Analysis of dose distribution in the 'Rind'--a volume outside the PTV--in 3-dimensional conformal radiation therapy of non-small cell lung cancer. <b>2003</b> , 66, 87-93	7
516	Combined modality therapy for non-small cell lung cancer, past, present, and future. <b>2003</b> , 42 Suppl 2, S35-40	4
515	Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. <b>2003</b> , 40, 79-84	70
514	Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting. <b>2003</b> , 41 Suppl 1, S115-21	14
513	Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer. <b>2003</b> , 41, 353-61	16
512	Histology-related variation in the treatment and survival of patients with lung carcinoma in Canada. <b>2003</b> , 42, 127-39	29
511	Management of the irradiated bronchus after lobectomy for lung cancer. <b>2003</b> , 76, 180-5; discussion 185-6	12

510	Results of clinical trials of multimodality therapy for resectable nonsmall-cell lung cancer. <b>2003</b> , 15, 431-7		
509	Results of clinical trials for locally advanced and metastatic nonsmall-cell lung cancer. <b>2003</b> , 15, 438-47		3
508	Combined modality treatment of non-small-cell lung cancer. <b>2003</b> , 2, 477-90		4
507	Lung Cancer. <b>2003</b> ,		11
506	Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study. <b>2003</b> , 14, 116-22		40
505	Surgical Oncology. <b>2003</b> ,		0
504	Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 1285-92	2.2	369
503	A systematic overview of radiation therapy effects in non-small cell lung cancer. <b>2003</b> , 42, 493-515		42
502	Radiotherapy patterns of care study in lung carcinoma. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 4553-9	2.2	77
501	Guidelines on treatment of stage IIIB non-small cell lung cancer. <b>2003</b> , 123, 2215-2255		60
500	Superior Vena Cava Syndrome. <b>2003</b> , 576-581		
499	Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer. <b>2003</b> , 26, S85-91		13
498	. <b>2003</b> , 26, S85-S91		7
497	[Sequential chemo-radiation in non-small cell lung cancer: a retrospective study of 100 patients]. <b>2003</b> , 9, 215-23		
496	Recent Advances in the Treatment of Stage IIIA Lung Cancer. <b>2003</b> , 10, 100-110		
495	Preoperative irradiation combined with chemotherapy impairs healing of bronchial anastomosis during the early postoperative period in rats. <b>2003</b> , 199, 1-12		3
494	Implementation of Multidisciplinary Care in the Treatment of Patients with Lung Cancer. <b>2003</b> , 1-24		
493	Radiotherapy for Locally Advanced Lung Cancer. <b>2003</b> , 46, 29		1



492	Concurrent Docetaxel/Cisplatin and Thoracic Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer. <b>2004</b> , 57, 257		2
491	Concurrent Chemoradiation with Weekly Paclitaxel in Locally Advanced Non-small Cell Lung Cancer. <b>2004</b> , 57, 351		2
490	Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. <b>2004</b> , 15, 1033-41		54
489	A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer. <b>2004</b> , 15, 399-409		16
488	Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 4971-8	2.2	139
487	Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 254-61	2.2	188
486	Tumor-infiltrating lymphocytes and interleukin-2: dose and schedules of administration in the treatment of metastatic cancer. <b>2004</b> , 19, 730-7		21
485	Paclitaxel for non-small cell lung cancer. <b>2004</b> , 5, 1771-80		70
484	Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging. <b>2004</b> , 15, 389-98		48
483	Weekly paclitaxel and nedaplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a phase I/II study. <b>2004</b> , 34, 647-53		9
482	Radiation esophagitis: Predictive factors and preventive strategies. <b>2004</b> , 14, 280-6		39
481	A practical approach to pulmonary risk assessment in the radiotherapy of lung cancer. <b>2004</b> , 14, 298-307		29
480	Management of unresectable stage III non-small cell lung cancer: the role of combined chemoradiation. <b>2004</b> , 14, 326-34		23
479	The care of the lung cancer patient in the 21st century: a new age. <b>2004</b> , 31, 11-5		37
478	Can the use of amifostine improve cure rates for patients with advanced non-small cell lung cancer?. <b>2004</b> , 31, 52-8		1
477	Signaling pathways in NSCLC as a predictor of outcome and response to therapy. <b>2004</b> , 182, 151-62		35
476	Predictors of acute esophagitis in patients with non-small-cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiotherapy followed by surgery. <b>2004</b> , 60, 1106-12		45
475	Comparison of the efficacy and acute toxicity of weekly versus daily chemoradiotherapy for non-small-cell lung cancer: a meta-analysis. <b>2004</b> , 58, 196-203		27

474	Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. <b>2004</b> , 58, 1106-13	119
473	Management and costs of treating lung cancer patients in a university hospital. <b>2004</b> , 22, 435-44	33
472	Radiation and third-generation chemotherapy. <b>2004</b> , 18, 55-80	31
471	[Targeted therapies in thoracic oncology]. <b>2004</b> , 21, 527-37	1
470	Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data. <b>2004</b> , 18, 41-53	31
469	[Treatment of non-small cell lung cancer (2003 update)]. <b>2004</b> , 21, 175-8	0
468	Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. <b>2004</b> ,	
467	Induction chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. <b>2004</b> , 18, 81-90	6
466	Concurrent radiochemotherapy in the treatment of locally advanced non-small cell lung cancer. <b>2004</b> , 18, 91-100	2
465	Percutaneous radiofrequency ablation of lung neoplasms: initial therapeutic response. <b>2004</b> , 15, 463-70	190
464	A randomised clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer. <b>2004</b> , 43, 309-16	36
463	A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer. <b>2004</b> , 45, 243-53	13
462	Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. <b>2004</b> , 46, 87-98	351
461	A phase II trial of preoperative concurrent radiation therapy and weekly paclitaxel/carboplatin for patients with locally advanced non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2004</b> , 6, 33-42	4.9 8
460	Biologic premises of combined radiation therapy and chemotherapy in lung cancer. <b>2004</b> , 18, 29-40	4
459	Radiation therapy. <b>2004</b> , 18, 1-12	6
458	Multidisciplinary management of lung cancer. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 379-92	59.2 709
457	Chemo-radiotherapy for stage III unresectable non-small cell lung cancer?long-term results of a prospective study. <b>2004</b> ,	

456	Chemo-radiotherapy for stage III unresectable non-small cell lung cancer long-term results of a prospective study. <b>2004</b> , 98, 1080-6	5
455	Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer. <b>2004</b> , 78, 1200-5; discussion 1206	127
454	Radiation treatment of lung cancer--patterns of practice in Canada. <b>2004</b> , 71, 167-74	14
453	Stage III non-small-cell lung cancer treated with high-dose hyperfractionated radiation therapy and concurrent low-dose daily chemotherapy with or without weekend chemotherapy: retrospective analysis of 301 patients. <b>2004</b> , 27, 350-60	5
452	Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience. <b>2004</b> , 27, 164-71	79
451	Preliminary results of a phase II study of weekly paclitaxel (PTX) and carboplatin (CBDCA) administered concurrently with thoracic radiation therapy (TRT) followed by consolidation chemotherapy with PTX/CBDCA for stage III unresectable non-small-cell lung cancer (NSCLC). <b>2004</b> , 27, 603-10	15
450	Therapy for Stage IIIA, IIIB and IV NonSmall Cell Lung Cancer. <b>2004</b> , 11, 161-174	
449	Interfraction interval in patients with stage III non-small-cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy: final results in 536 patients. <b>2004</b> , 27, 616-25	7
448	Estimating the benefit and cost of radiotherapy for lung cancer. <b>2004</b> , 20, 545-51	18
447	Re-examining the role of elective nodal irradiation: finding ways to maximize the therapeutic ratio. <b>2005</b> , 28, 597-602	8
446	Radiation-Induced Lung and Heart Toxicity. <b>2005</b> , 351-365	1
445	Dosimetric and clinical predictors for radiation-induced esophageal injury. <b>2005</b> , 61, 335-47	119
444	Pulmonary function changes after radiotherapy in non-small-cell lung cancer patients with long-term disease-free survival. <b>2005</b> , 62, 639-44	71
443	Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy. <b>2005</b> , 62, 995-1002	64
442	Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer. <b>2005</b> , 63, 1029-36	6
441	Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer. <b>2005</b> , 63, 1037-44	9
440	Current standards and ongoing controversies in the management of locally advanced non-small cell lung cancer. <b>2005</b> , 32, 284-92	13
439	A case against surgery for most IIIa non-small cell lung cancer. <b>2005</b> , 32, S6-8	4

438	Pilot study of accelerated radiotherapy with concurrent chemotherapy for stage III non-small cell lung cancer. <b>2005</b> , 32, S9-12			5
437	Non-small cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and fibrosis. <b>2005</b> , 32, S42-54			137
436	Combined modality trials in unresectable stage III non-small cell lung cancer: the Cancer and Leukemia Group B experience. <b>2005</b> , 32, S114-8			6
435	Southwest Oncology Group: two decades of experience in non-small cell lung cancer. <b>2005</b> , 32, S119-21			4
434	Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer. <b>2005</b> , 5, 71			7
433	Recent advances and future perspectives in the management of lung cancer. <b>2005</b> , 42, 540-610			1
432	Three-times-daily radiotherapy with induction chemotherapy in locally advanced non-small cell lung cancer. Feasibility and toxicity study. <b>2005</b> , 181, 363-71			17
431	Multimodale Therapie des lokal fortgeschrittenen NSCLC. <b>2005</b> , 2, 254-259			1
430	Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: a phase II trial with special reference to the hemoglobin level as prognostic parameter. <b>2005</b> , 131, 261-9			19
429	Radioprotectors and Chemoprotectors in the Management of Lung Cancer. <b>2005</b> , 123-134			
428	Translational Research in Radiation Oncology of Lung Cancer. <b>2005</b> , 481-493			
427	Radiochemotherapy in Locally Advanced Non-Small Cell Lung Cancer. <b>2005</b> , 207-222			
426	Will future progress in non-small-cell lung cancer be step by step... or by leaps and bounds?. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 5859-61	2.2		2
425	Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. <b>2005</b> , 97, 499-506			124
424	The role of surgery in N2 non-small cell lung cancer. <b>2005</b> , 11, 5033s-5037s			20
423	Hematologic Toxicity in Lung Cancer. <b>2005</b> , 339-350			
422	Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 5910-7	2.2		444
421	Treatment of advanced non-small cell lung cancer in the elderly. <b>2005</b> , 26, 289-97			6

420	Treatment of locally advanced non-small cell lung cancer with combination of chemotherapy and radiation. <b>2005</b> , 26, 273-7		4
419	Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 5883-91	2.2	347
418	A phase II study of docetaxel and infusional cisplatin in advanced non-small-cell lung cancer. <b>2005</b> , 51, 120-5		11
417	Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812). <b>2005</b> , 35, 195-201		59
416	Cancer de pulm?n no microc?tico. <b>2005</b> , 9, 1550-1562		
415	Current perspectives on treatment strategies for locally advanced, unresectable stage III non-small cell lung cancer. <b>2005</b> , 50, S17-S24		14
414	Amlioration du pronostic des cancers bronchiques non ^petites cellules : mythe ou r?alit??. <b>2005</b> , 22, 137-142		3
413	State of the art in therapy for non-small cell lung cancer. <b>2005</b> , 23, 427-42		58
412	Curcumin enhances Vinorelbine mediated apoptosis in NSCLC cells by the mitochondrial pathway. <b>2005</b> , 331, 1245-52		115
411	Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534. <i>Clinical Lung Cancer</i> , <b>2005</b> , 7, 47-53	4.9	27
410	The role of docetaxel in N2 locally advanced non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2005</b> , 7 Suppl 3, S87-92	4.9	1
409	Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection?. <b>2005</b> , 49, 109-15		87
408	Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer. <b>2005</b> , 50, 235-45		14
407	La survie des cancers bronchiques non ^petites cellules s?est elle amlior?e au cours de ces vingt derni?res ann?es ?. <b>2005</b> , 61, 31-35		2
406	Study of the effect of standardized chemotherapy order forms on prescribing errors and anti-emetic cost. <b>2005</b> , 11, 21-30		22
405	Taxanes in the treatment of non-small cell lung cancer. <b>2006</b> , 5, 181-91		5
404	The role of radiation therapy in thoracic tumors. <b>2006</b> , 20, 363-400		17
403	Is trimodality approach better then bimodality in stage IIIA, N2 positive non-small cell lung cancer?. <b>2006</b> , 53, 323-30		21

402	Current Update on the Management of Locally Advanced Non-small Cell Lung Cancer. <b>2006</b> , 5, 1	
401	Non-Small-Cell Lung Cancer. <b>2006</b> ,	
400	Short-Term Restaging of Patients with Non-small Cell Lung Cancer Receiving Chemotherapy. <b>2006</b> , 1, 425-429	4
399	Short-Term Restaging of Patients with Non-small Cell Lung Cancer Receiving Chemotherapy. <b>2006</b> , 1, 425-429	4
398	Age is independent of comorbidity influencing patient selection for combined modality therapy for treatment of stage III nonsmall cell lung cancer (NSCLC). <b>2006</b> , 29, 252-7	51
397	NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel. <b>2006</b> , 95, 601-6	77
396	Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume. <b>2006</b> , 64, 449-54	79
395	Effect of histologic type on recurrence pattern in radiation therapy for medically inoperable patients with stage I non-small-cell lung cancer. <b>2006</b> , 184, 347-53	11
394	Phase I study of weekly cisplatin, vinorelbine, and concurrent thoracic radiation therapy in patients with locally advanced non-small-cell lung cancer. <b>2006</b> , 11, 314-9	1
393	Future directions in the second-line treatment of non-small cell lung cancer. <b>2006</b> , 33, S45-51	9
392	Recent Clinical Trials in Non-Small Cell Lung Cancer. <b>2006</b> , 2, 81-99	
391	Trends in the pattern of care for lung cancer and their correlation with new clinical evidence: experiences in a university-affiliated medical center. <b>2006</b> , 21, 408-14	8
390	Free Flap Head and Neck Reconstruction After Cancer Therapy: Current State of the Art. <b>2006</b> , 2, 67-72	
389	The cancer and leukemia group B respiratory committee. <b>2006</b> , 12, 3581s-8s	2
388	[Multimodal therapy of small cell and non-small cell lung carcinoma]. <b>2007</b> , 132, 1221-4	2
387	Role of bevacizumab for the treatment of non-small-cell lung cancer. <b>2007</b> , 3, 131-9	11
386	Scalpels, beams, drugs, and dreams: challenges of stage IIIA-N2 non-small-cell lung cancer. <b>2007</b> , 99, 415-8	15
385	Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4146-52	2.2 81

384	3D-conformal radiotherapy for inoperable non-small-cell lung cancer - A single centre experience. <b>2007</b> , 41, 133	2
383	M19-02: Bi-modality versus tri-modality therapy in stage IIIa NSCLC: Where does the data lead us?. <b>2007</b> , 2, S208-S209	
382	Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers. <b>2007</b> , 30, 258-63	8
381	[Chemoradiation for locally advanced non-small cell lung cancer]. <b>2007</b> , 11, 67-76	3
380	The role of radiotherapy in lung cancer: where is the evidence?. <b>2007</b> , 83, 203-13	48
379	Paradigms in chemoradiotherapy. <b>2007</b> , 5, 277-285	
378	Treatment options in stage IIIB non-small cell lung cancer: Making the proper choice. <b>2007</b> , 5, 287-292	
377	Cisplatin plus gemcitabine with or without vinorelbine as induction chemotherapy prior to radical locoregional treatment for patients with stage III non-small-cell lung cancer (NSCLC): results of a prospective randomized study. <b>2007</b> , 55, 173-80	7
376	[Stage IIIA and IIIB non-small cell lung cancer: results of chemotherapy combined with radiation therapy and analysis of prognostic factors]. <b>2007</b> , 43, 358-65	5
375	Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer. <i>Core Evidence</i> , <b>2007</b> , Volume 2, 0-0	4-9
374	Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma. <b>2007</b> , 2, 203-9	8
373	Prevention of radiochemotherapy-induced esophagitis with glutamine: results of a pilot study. <b>2007</b> , 69, 342-9	40
372	Comparison of CT and positron emission tomography/CT coregistered images in planning radical radiotherapy in patients with non-small-cell lung cancer. <b>2007</b> , 51, 386-93	18
371	Carcinoma de pulmón no microcítico. Estadios IIIA y B. Resultados del tratamiento combinado (quimioterapia y radioterapia) y análisis de factores pronósticos. <b>2007</b> , 43, 358-365	2
370	The synergistic effect of dimethylamino benzoylphenylurea (NSC #639829) and X-irradiation on human lung carcinoma cell lines. <b>2007</b> , 59, 781-7	5
369	The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. <b>2008</b> , 88, 43-50	25
368	Pneumonectomy after chemoradiation: the Dana-Farber Cancer Institute/Brigham and Women's Hospital experience. <b>2008</b> , 112, 1106-13	34
367	Elective Nodal Irradiation (ENI) doesn't appear to provide a clear benefit for patients with unresectable non-small-cell lung cancer (NSCLC). <b>2008</b> , 72, 311-2	16

366	Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small-cell lung cancer. <b>2008</b> , 71, 407-13		11
365	Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico clinical trial. <b>2008</b> , 71, 1103-10		61
364	Cytoprotection for Radiation-Associated Normal Tissue Injury. <b>2008</b> , 302-322		2
363	Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress?. <i>Clinical Lung Cancer</i> , <b>2008</b> , 9, 85-91	4.9	6
362	Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B. <b>2008</b> , 35, 470-83		5
361	Non-small cell lung cancer in the elderly: defining treatment options. <b>2008</b> , 35, 590-6		23
360	The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer. <b>2008</b> , 59, 232-9		77
359	Continuous hyperfractionated accelerated radiation therapy week-end less in combination with neoadjuvant chemotherapy for the treatment of stage III non-small-cell lung cancer. <b>2008</b> , 60, 75-82		7
358	Involvement of p53-transactivated Puma in cisplatin-induced renal tubular cell death. <b>2008</b> , 83, 550-6		26
357	Dosimetric analysis of the patterns of local failure observed in patients with locally advanced non-small cell lung cancer treated with neoadjuvant chemotherapy and concurrent conformal (3D-CRT) chemoradiation. <b>2008</b> , 88, 342-50		18
356	BLP-25 liposomal vaccine: a promising potential therapy in non-small-cell lung cancer. <b>2008</b> , 2, 37-45		22
355	Definitive chemoradiotherapy for non-small cell lung cancer with N2 disease. <b>2008</b> , 18, 393-401		5
354	Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 644-9	2.2	132
353	Should randomized clinical trials be required for proton radiotherapy? An alternative view. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 2438-9	2.2	37
352	Controversies in the management of stage IIIA non-small-cell lung cancer. <b>2008</b> , 8, 1913-29		3
351	Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. <b>2008</b> , 13 Suppl 1, 5-13		262
350	Evaluation of trends in the cost of initial cancer treatment. <b>2008</b> , 100, 888-97		285
349	Phase I/II study of biweekly paclitaxel and radiation in androgen-ablated locally advanced prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 2973-8	2.2	27



348	Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5755-60	2.2	385
347	Radiation pneumonitis and esophagitis in thoracic irradiation. <b>2006</b> , 128, 43-64		24
346	Concurrent chemoradiotherapy with cisplatin and vinorelbine for stage III non-small cell lung cancer. <b>2008</b> , 3, 617-22		37
345	Increased efficiency for performing colony formation assays in 96-well plates: novel applications to combination therapies and high-throughput screening. <b>2008</b> , 44, ix-xiv		34
344	Management of Locally Advanced Non-small Cell Lung Cancer. <b>2009</b> , 8, 1		
343	Post-treatment effects of erythropoietin and nordihydroguaiaretic acid on recovery from cisplatin-induced acute renal failure in the rat. <b>2009</b> , 24 Suppl, S170-5		14
342	A phase II study of cisplatin and irinotecan as induction chemotherapy followed by accelerated hyperfractionated thoracic radiotherapy with daily low-dose carboplatin in unresectable stage III non-small cell lung cancer: JCOG 9510. <b>2009</b> , 39, 784-90		2
341	Developing an effective lung cancer program in a community hospital setting. <i>Clinical Lung Cancer</i> , <b>2009</b> , 10, 239-43	4.9	14
340	Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2009</b> , 10 Suppl 1, S30-4	4.9	21
339	Radiotherapy Planning Complexity and Survival after Treatment of Advanced Stage Lung Cancer in the Elderly. <b>2009</b> , 115, 4865-4873		8
338	A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study. <b>2009</b> , 74, 1397-404		33
337	Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy. <b>2009</b> , 73, 810-7		43
336	Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer. <b>2009</b> , 73, 802-9		5
335	Phase I study of oral S-1 plus Cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. <b>2009</b> , 75, 109-14		9
334	Survival and risk factors of surgically treated mediastinal invasion T4 non-small cell lung cancer. <b>2009</b> , 88, 372-8		38
333	Prevention of acute radiation-induced esophagitis with glutamine in non-small cell lung cancer patients treated with radiotherapy: evaluation of clinical and dosimetric parameters. <b>2009</b> , 63, 393-9		46
332	A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer. <b>2009</b> , 64, 187-93		24
331	Induction chemotherapy and chemoradiation therapy for inoperable locally advanced non-small-cell lung cancer: a single-institution review of two different regimens. <i>Clinical Lung Cancer</i> , <b>2009</b> , 10, 124-9	4.9	6

330	ACR appropriateness criteria on nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent. <b>2009</b> , 6, 85-95	12
329	A phase II trial of induction chemotherapy followed by continuous hyperfractionated accelerated radiotherapy in locally advanced non-small-cell lung cancer. <b>2009</b> , 93, 396-401	14
328	Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. <b>2009</b> , 374, 379-86	991
327	Advances in radiotherapy for tumors involving the mediastinum. <b>2009</b> , 19, 133-41	3
326	RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy ("ping-pong trial") followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer. <b>2009</b> , 4, 80-6	16
325	Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. <b>2009</b> , 4, 1117-25	32
324	Antiangiogenic agents in the treatment of nonsmall cell lung cancer: reality and hope. <b>2010</b> , 22, 79-85	5
323	Non-small cell lung cancer. <b>2010</b> , 8, 740-801	457
322	Non-small cell lung cancer in stages I-III B: Long-term results of definitive radiotherapy with doses $\square$ 80 Gy in standard fractionation. <b>2010</b> , 186, 551-7	16
321	Nonresected non-small-cell lung cancer in Stages I through III B: accelerated, twice-daily, high-dose radiotherapy—a prospective Phase I/II trial with long-term follow-up. <b>2010</b> , 77, 1345-51	11
320	Is pulmonary function damaged by neoadjuvant lung cancer therapy? A comprehensive serial time-trend analysis of pulmonary function after induction radiochemotherapy plus surgery. <b>2010</b> , 139, 1457-63	17
319	Combined modality therapy for stage III non-small-cell lung cancer. <b>2010</b> , 20, 186-91	20
318	Underutilization of radiotherapy for lung cancer in New South Wales, Australia. <b>2010</b> , 116, 686-94	25
317	Continuous hyperfractionated accelerated radiotherapy (CHART) and non-conventionally fractionated radiotherapy in the treatment of non-small cell lung cancer: a review and consideration of future directions. <b>2010</b> , 22, 356-64	12
316	Comparative survival in patients with postresection recurrent versus newly diagnosed non-small-cell lung cancer treated with radiotherapy. <b>2010</b> , 76, 1100-5	31
315	Neoadjuvant chemoradiation with paclitaxel/carboplatin for selected Stage III non-small-cell lung cancer: long-term results of a trimodality Phase II protocol. <b>2010</b> , 76, 1376-81	10
314	High-dose conformal radiotherapy for patients with stage III non-small-cell lung carcinoma. <b>2010</b> , 78, 645-50	15
313	Treatment-related pneumonitis and acute esophagitis in non-small-cell lung cancer patients treated with chemotherapy and helical tomotherapy. <b>2010</b> , 78, 651-8	63

312	The effects of comorbidity and age on RTOG study enrollment in Stage III non-small cell lung cancer patients who are eligible for RTOG studies. <b>2010</b> , 78, 1394-9		26
311	Large volume unresectable locally advanced non-small cell lung cancer: acute toxicity and initial outcome results with rapid arc. <b>2010</b> , 5, 94		31
310	Risk Factors for Fatal Hemoptysis after Concurrent Chemoradiation Therapy in Patients with Non-Small Cell Lung Carcinoma. <b>2010</b> , 46, 19		7
309	Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3739-45	2.2	215
308	Clinical Management of Lung Cancer. <b>2010</b> , 437-445		
307	The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors. <b>2010</b> , 28, 413-423		16
306	Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 56-62	2.2	224
305	The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors. <b>2010</b> , 28, 413-23		28
304	Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3299-306	2.2	187
303	[Prevention, diagnosis, therapy, and follow-up of lung cancer]. <b>2010</b> , 64 Suppl 2, e1-164		85
302	Issues in Data Analysis. <b>2010</b> , 345-398		
301	Stage III vs. stage IV lung cancer: "Crossing a Great Divide". <b>2010</b> , 67, 1-3		6
300	[Normal tissue tolerance to external beam radiation therapy: esophagus]. <b>2010</b> , 14, 327-35		4
299	Pneumonectomy for lung cancer after preoperative concurrent chemotherapy and high-dose radiation. <b>2010</b> , 89, 200-6; discussion 206		36
298	Fundamentals of Clinical Trials. <b>2010</b> ,		244
297	A critical appraisal of the adjuvant chemotherapy guidelines for patients with completely resected T3N0 non-small-cell lung cancer. <b>2010</b> , 49, 480-4		12
296	Status of particle therapy for lung cancer. <b>2011</b> , 50, 745-56		25
295	La radiothérapie conformationnelle thoracique dans ses limites. <b>2011</b> , 3, 360-364		

294	Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study. <b>2011</b> , 72, 327-32		22
293	Principles of Anticancer Drug Development. <b>2011</b> ,		
292	Management of non-small-cell lung cancer in the older adult. <b>2011</b> , 68, 311-21		8
291	Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival. <b>2011</b> , 81, 985-91		15
290	Radiotherapy and Third Generation Concurrent Chemotherapy Agents. <i>Medical Radiology</i> , <b>2011</b> , 291-312	0.2	2
289	Clinical Research in Radiation Oncology of Lung Cancer: Why We Fail(ed)?. <i>Medical Radiology</i> , <b>2011</b> , 809-818		
288	Radiochemotherapy in Locally Advanced Nonsmall-Cell Lung Cancer. <i>Medical Radiology</i> , <b>2011</b> , 409-431	0.2	1
287	Systemic Therapy for Lung Cancer for the Radiation Oncologist. <i>Medical Radiology</i> , <b>2011</b> , 247-266	0.2	
286	Radiation-Induced Lung and Heart Toxicity. <i>Medical Radiology</i> , <b>2011</b> , 609-625	0.2	
285	Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer. <b>2011</b> , 2, 59-67		10
284	Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer. <b>2011</b> , 6, 934-41		53
283	Four-dimensional Radiation Therapy for Non-Small Cell Lung Cancer: A Clinical Perspective. <i>Medical Radiology</i> , <b>2011</b> , 157-172	0.2	
282	Review of chemoradiotherapy for high-risk prostate cancer. <b>2011</b> , 6, 64-8		6
281	Combined Radiotherapy and Chemotherapy: Theoretical Considerations and Biological Premises. <i>Medical Radiology</i> , <b>2011</b> , 267-273	0.2	
280	Chemotherapy significantly increases the risk of radiation pneumonitis in radiation therapy of advanced lung cancer. <b>2011</b> , 34, 160-4		41
279	Radioprotectors and Chemoprotectors in the Management of Lung Cancer. <i>Medical Radiology</i> , <b>2011</b> , 223-245	0.2	
278	c-Myc down-regulation is involved in proteasome inhibitor-mediated enhancement of radiotherapeutic efficacy in non-small cell lung cancer. <b>2012</b> , 40, 385-90		12
277	Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. <b>2011</b> , 6, 1079-86		11

276	Survival of patients with clinical stage IIIA non-small cell lung cancer after induction therapy: age, mediastinal downstaging, and extent of pulmonary resection as independent predictors. <b>2011</b> , 141, 48-58		42
275	Lung cancer: New biological insights and recent therapeutic advances. <b>2011</b> , 61, 91-112		329
274	Multidisciplinary approach in stage III non-small-cell lung cancer: standard of care and open questions. <b>2011</b> , 13, 629-35		4
273	Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab: the NEAR trial. <b>2011</b> , 117, 2986-94		49
272	Preclinical and pilot clinical studies of docetaxel chemoradiation for Stage III non-small-cell lung cancer. <b>2011</b> , 80, 1358-64		4
271	Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. <b>2011</b> , 103, 1452-60		807
270	A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer. <b>2011</b> , 22, 336-42		52
269	A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706. <b>2011</b> , 41, 25-31		6
268	Hematological Toxicity in Lung Cancer. <i>Medical Radiology</i> , <b>2011</b> , 597-608	0.2	
267	Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2305-11	2.2	48
266	Lung adenocarcinoma. <b>2012</b> , 136-165		
265	Prognostic significance of tumor size in patients with stage III non-small-cell lung cancer: a surveillance, epidemiology, and end results (SEER) survey from 1998 to 2003. <b>2012</b> , 7, 1479-84		44
264	Molecular-Based Decision Making for Personalized Cancer Management. <b>2012</b> ,		
263	Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). <b>2012</b> , 13, 671-8		166
262	Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung. <b>2012</b> , 84, 456-63		81
261	Lung Cancer: Treatment. <b>2012</b> , 801-809		
260	Multimodality therapy improves survival in elderly patients with locally advanced non-small cell lung cancer: a retrospective analysis. <b>2012</b> , 3, 104-110		8
259	Treatment of lung cancer. <b>2012</b> , 50, 961-74		62

258	Designs for Clinical Trials. <b>2012,</b>		3
257	Lung Cancer in Elderly. <b>2012,</b>		1
256	. <b>2012,</b>		1
255	Risk associated with bilobectomy after neoadjuvant concurrent chemoradiotherapy for stage IIIA-N2 non-small-cell lung cancer. <b>2012, 36, 1199-205</b>		7
254	A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer (JCOG9901DI). <b>2012, 69, 1625-31</b>		5
253	Radiotherapy for stage III non-small-cell lung carcinoma in the elderly (age $\geq$ 70 years). <i>Clinical Lung Cancer, 2013, 14, 674-9</i>	4.9	11
252	Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601. <b>2013, 81, 91-6</b>		17
251	Lung Cancer Imaging. <b>2013,</b>		1
250	Predicting 2-year survival for radiation regimens in advanced non-small cell lung cancer. <b>2013, 25, 697-705</b>		8
249	ACR appropriateness criteria nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent. <b>2013, 10, 654-64</b>		15
248	DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)--a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume. <b>2013, 8, 49</b>		15
247	Lung Radiotherapy. <b>2013, 65-86</b>		
246	Toxicity of concurrent radiochemotherapy for locally advanced non--small-cell lung cancer: a systematic review of the literature. <i>Clinical Lung Cancer, 2013, 14, 481-7</i>	4.9	33
245	Dose-escalation study of thoracic radiotherapy in combination with pemetrexed plus Cisplatin followed by pemetrexed consolidation therapy in Japanese patients with locally advanced nonsquamous non-small-cell lung cancer. <i>Clinical Lung Cancer, 2013, 14, 62-9</i>	4.9	16
244	Evolution of modern-era radiotherapy strategies for unresectable advanced non-small-cell lung cancer. <b>2013, 2, 213-225</b>		1
243	A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer. <i>Frontiers in Oncology, 2013, 3, 219</i>	5.3	9
242	Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancer. <i>Cancer Journal (Sudbury, Mass ), 2013, 19, 222-30</i>	2.2	9
241	Integration of targeted therapy in the management of locally advanced, unresectable non-small-cell lung cancer. <b>2013, 2, 75-85</b>		

240	"When Roscius was an actor in Rome-" care for the elderly with N2-positive non-small-cell lung cancer. <b>2013</b> , 8, 670-2		
239	Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy. <b>2013</b> , 4, 736-54		65
238	50 Years of progress in the systemic therapy of non-small cell lung cancer. <b>2014</b> , 177-89		75
237	Current status of induction treatment for N2-Stage III non-small cell lung cancer. <b>2014</b> , 62, 651-9		10
236	Combinations of Radiation Therapy and Chemotherapy for Non-Small Cell and Small-Cell Lung Carcinoma. <b>2014</b> , 353-378		
235	Strategies of dose escalation in the treatment of locally advanced non-small cell lung cancer: image guidance and beyond. <i>Frontiers in Oncology</i> , <b>2014</b> , 4, 156	5.3	12
234	Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced non-small cell lung cancer. <b>2014</b> , 37, 148-53		22
233	Evidence based radiation oncology with existing technology. <b>2014</b> , 19, 259-66		13
232	Pulmonary resection after chemoradiotherapy for advanced non-small cell lung cancer: the impact of presurgical radiation therapy. <b>2014</b> , 44, 123-30		4
231	A phase I study of temsirolimus and thoracic radiation in non--small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2014</b> , 15, 119-23	4.9	15
230	Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer. <b>2014</b> , 83, 67-72		0
229	Pretreatment clinical mediastinal nodal bulk and extent do not influence survival in N2-positive stage IIIA non-small cell lung cancer patients treated with trimodality therapy. <b>2014</b> , 21, 2083-90		21
228	Outcome and toxicity profiles in the treatment of locally advanced lung cancer with volumetric modulated arc therapy. <b>2014</b> , 140, 1937-45		3
227	Steadily improving survival in lung cancer. <i>Clinical Lung Cancer</i> , <b>2014</b> , 15, 331-7	4.9	17
226	Tumours of the lung and mediastinum. <b>2014</b> , 209-236		
225	Molecular Target Treatment for Personalized Radiotherapy in Lung Cancer. <b>2014</b> , 390-405		
224	Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer. <b>2015</b> , 10, 1685-93		38
223	Current Standards and Clinical Trials in Systemic Therapy for Stage III Lung Cancer: What Is New?. <b>2015</b> , e442-7		4

222	Preliminary results of proton-beam therapy for stage III non-small-cell lung cancer. <b>2015</b> , 22, e370-5		7
221	Emerging Treatment Paradigms in Radiation Oncology. <b>2015</b> , 21, 3393-401		22
220	A review of the management of elderly patients with non-small-cell lung cancer. <b>2015</b> , 26, 451-63		53
219	Combining Systemic Therapies with Radiation in Non-Small Cell Lung Cancer. <b>2015</b> , 07,		
218	Nomogram to Predict Occult N2 Lymph Nodes Metastases in Patients With Squamous Nonsmall Cell Lung Cancer. <b>2015</b> , 94, e2054		12
217	Retrospective estimate of the quality of intensity-modulated radiotherapy plans for lung cancer. <b>2015</b> , 67, 136-141		2
216	Assessing the Effects of Concurrent versus Sequential Cisplatin/Radiotherapy on Immune Status in Lung Tumor-Bearing C57BL/6 Mice. <b>2015</b> , 3, 741-50		8
215	Historical trends of radiotherapy use in prevalent malignancies over 38 years in SEER. <b>2015</b> , 4, 11-17		3
214	Intensity-Modulated Radiation Therapy. <b>2015</b> ,		3
213	Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial. <b>2015</b> , 93, 72-81		48
212	Radiation esophagitis. <b>2015</b> , 139, 827-30		65
211	Fundamentals of Clinical Trials. <b>2015</b> ,		128
210	Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2660-6	2.2	170
209	Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration. <b>2015</b> , 16, 47		6
208	Radiosensitizing effect of carboplatin and paclitaxel to carbon-ion beam irradiation in the non-small-cell lung cancer cell line H460. <b>2015</b> , 56, 229-38		25
207	New Therapeutic Strategies in Lung Cancers. <b>2015</b> ,		0
206	Adjuvant chemotherapy plus radiotherapy is superior to chemotherapy following surgical treatment of stage IIIA N2 non-small-cell lung cancer. <b>2016</b> , 9, 921-8		6
205	Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment. <b>2016</b> , 9, 3671-81		2



204	Pros: concurrent chemo-radiotherapy remains the ideal treatment in fit patients with large volume unresectable stage III non-small cell lung cancer. <b>2016</b> , 5, 190-4		
203	Phase 3 Randomized Low-Dose Paclitaxel Chemoradiotherapy Study for Locally Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , <b>2016</b> , 6, 260	53	6
202	Isolated Nodal Failure after Stereotactic Body Radiotherapy for Lung Cancer: The Role for Salvage Mediastinal Radiotherapy. <b>2016</b> , 11, 1558-64		17
201	Radio(chemo)therapy in locally advanced nonsmall cell lung cancer. <b>2016</b> , 25, 65-70		15
200	Optimum treatment for mediastinal lymph node positive (N2) resectable non-small cell lung cancer: what is the role for surgery?. <b>2016</b> , 16, 1131-1144		
199	Role of surgery in N2 NSCLC: pros. <b>2016</b> , 46, 1168-1173		3
198	Multimodality Therapy for NSCLC. <b>2016</b> , 170, 151-63		5
197	Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced non-small cell lung cancer. <b>2016</b> , 46, 1008-1014		7
196	Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy. <b>2016</b> , 95, e4280		9
195	Interaction of Chemotherapy and Radiation. <b>2016</b> , 63-79.e4		3
194	Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer. <b>2016</b> , 27, 590-9		28
193	CT scan prior to radiotherapy in unresectable, locally advanced, non-small cell carcinoma of the lung: is it always necessary?. <b>2017</b> , 19, 105-110		
192	Lycopene in the Prevention of Radiation-Induced Esophagitis. <b>2017</b> , 69, 319-329		7
191	Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). <b>2017</b> , 12, 697-703		12
190	Single-center comparison of multiple chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small-cell lung cancer. <b>2017</b> , 79, 381-387		5
189	Salvage Surgery After Definitive Chemoradiotherapy for Non-small Cell Lung Cancer. <b>2017</b> , 29, 233-241		34
188	Cancer of the Lung. <b>2017</b> , 1-30		0
187	Treatment of Locally Advanced Non-Small Cell Lung Cancer. <b>2017</b> , 31, 45-57		6

186	Acute Side Effects of Radiation Therapy. <b>2017</b> ,		3
185	Lung Cancer and Other Thoracic Malignancies. <i>Medical Radiology</i> , <b>2017</b> , 45-80	0.2	
184	Management of stage III non-small cell lung cancer. <b>2017</b> , 44, 163-177		27
183	Optimale Therapie des nichtkleinzelligen Lungenkarzinoms im Stadium IIIB/C. <b>2017</b> , 20, 32-42		
182	Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy. <i>Frontiers in Oncology</i> , <b>2017</b> , 7, 197	5.3	18
181	Neoadjuvant Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , <b>2017</b> , 7, 281	5.3	6
180	Application of the new 8th TNM staging system for non-small cell lung cancer: treated with curative concurrent chemoradiotherapy. <b>2017</b> , 12, 122		18
179	Therapeutic management options for stage III non-small cell lung cancer. <b>2017</b> , 8, 1-20		127
178	Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy. <b>2017</b> , 6, 131-147		34
177	Breathing New Life Into Hypoxia-Targeted Therapies for Non-Small Cell Lung Cancer. <b>2018</b> , 110,		22
176	Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer. <b>2018</b> , 66, 114-121		25
175	The biology and management of non-small cell lung cancer. <b>2018</b> , 553, 446-454		1499
174	PARP Inhibition Combined With Thoracic Irradiation Exacerbates Esophageal and Skin Toxicity in C57BL6 Mice. <b>2018</b> , 100, 767-775		15
173	Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC. <b>2018</b> , 13, 1171-1182		9
172	Treatment of locally advanced, unresectable or medically inoperable stage III non-small-cell lung cancer; the past, present and future of chemoradiotherapy. <b>2018</b> , 4, 49-52		1
171	Analysis of the Relationship Between Response to Chemotherapy and Response to Radiation Therapy in Patients With Non-Small Cell Lung Cancer Receiving Sequential Treatment. <b>2018</b> , 41, 391-395		2
170	Concurrent chemoradiotherapy with weekly nedaplatin versus radiotherapy alone in elderly patients with non-small-cell lung cancer. <b>2018</b> , 20, 294-301		2
169	Identifying the Optimal Radiation Dose in Locally Advanced Non-Small-cell Lung Cancer Treated With Definitive Radiotherapy Without Concurrent Chemotherapy. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e131-e140	4.0	8

168	Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy-fortune favours the bold. <b>2018</b> , 7, S388-S392		2
167	S-1 plus cisplatin with concurrent radiotherapy for stage III non-small cell lung cancer: A meta-analysis (PRISMA) of randomized control trials. <b>2018</b> , 97, e13441		2
166	Non-small Cell Lung Cancer. <b>2018</b> , 293-321		
165	Making the Evidentiary Case for Universal Multidisciplinary Thoracic Oncologic Care. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, 294-300	4.9	10
164	Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. <b>2018</b> , 10, 931-940		8
163	Prophylactic Cranial Irradiation in Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 115	5.3	14
162	Variations in Initiation Dates of Chemotherapy and Radiation Therapy for Definitive Management of Inoperable Non-Small Cell Lung Cancer Are Associated With Decreases in Overall Survival. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e381-e390	4.9	1
161	Chemoradiotherapy in Elderly Patients With Non-Small-Cell Lung Cancer: Long-Term Follow-Up of a Randomized Trial (JCOG0301). <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e619-e627	4.9	16
160	Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?. <b>2019</b> , 21, 84		10
159	Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach. <b>2019</b> , 14, e0224027		4
158	GSVD- and tensor GSVD-uncovered patterns of DNA copy-number alterations predict adenocarcinomas survival in general and in response to platinum. <b>2019</b> , 3, 036104		8
157	Effect of 5-fluorouracil on cellular response to proton beam in esophageal cancer cell lines according to the position of spread-out Bragg peak. <b>2019</b> , 58, 475-482		5
156	Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes. <b>2019</b> , 36, 563-578		6
155	Absolute Clinical Radiation Oncology Review. <b>2019</b> ,		2
154	Real-World Treatment of Stage III NSCLC: The Role of Trimodality Treatment in the Era of Immunotherapy. <b>2019</b> , 14, 1430-1439		9
153	Management of Locally Advanced Lung Cancer. <b>2019</b> , 57-86		1
152	A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer. <b>2019</b> , 125, 2148-2153		0
151	Radiosensitizing Effect of Gadolinium Oxide Nanocrystals in NSCLC Cells Under Carbon Ion Irradiation. <b>2019</b> , 14, 328		9

150	Radiotherapy for patients with completely resected pathologic IIIA(N2) non-small-cell lung cancer: a retrospective analysis. <b>2019</b> , 11, 10901-10908		2
149	A Belief Rule Base Expert System for staging Non-Small Cell Lung Cancer under Uncertainty. <b>2019</b> ,		7
148	Survival and late toxicities following concurrent chemo-radiotherapy for locally advanced stage III non-small cell lung cancer: findings of a 10-year Australian single centre experience with long term clinical follow up. <i>Journal of Thoracic Disease</i> , <b>2019</b> , 11, 4241-4248	2.6	6
147	Cancer of the Lung: NonSmall Cell Lung Cancer and Small Cell Lung Cancer. <b>2020</b> , 1108-1158.e16		5
146	Chemoradiotherapy of locally-advanced non-small cell lung cancer: Analysis of radiation dose-response, chemotherapy and survival-limiting toxicity effects indicates a low $\alpha/\beta$ ratio. <b>2020</b> , 143, 58-65		5
145	Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage NSCLC. <b>2020</b> , 15, 176-189		17
144	Real-world incidence and cost of pneumonitis post-chemoradiotherapy for Stage III non-small-cell lung cancer. <b>2020</b> , 16, 4303-4313		4
143	The changing landscape of stage III lung cancer: a literature review. <b>2020</b> , 20, 675-686		1
142	A narrative review of toxicity of chemoradiation and immunotherapy for unresectable, locally advanced non-small cell lung cancer. <b>2020</b> , 9, 2040-2050		1
141	Surgical Management of Stage IIIA Non-small Cell Lung Cancer. <b>2020</b> , 9, 151-163		
140	Passion, Perseverance, and Quantum Leaps: Lung Cancer in the Twenty-First Century. <i>Clinics in Chest Medicine</i> , <b>2020</b> , 41, xi-xiii	5.3	1
139	The novel lncRNA PTTG3P is downregulated and predicts poor prognosis in non-small cell lung cancer. <b>2020</b> , 16, 931-940		4
138	Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. <b>2020</b> , 9,		9
137	The top 100 cited articles in lung cancer - a bibliometric analysis. <b>2020</b> , 24, 17-28		3
136	Passion, Perseverance, and Quantum Leaps: Lung Cancer in the Twenty-First Century. <i>Clinics in Chest Medicine</i> , <b>2020</b> , 41, ix-xi	5.3	1
135	Locally Advanced, Unresectable Non-Small Cell Lung Cancer. <b>2020</b> , 22, 31		7
134	Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab. <b>2020</b> , 11, 1005-1014		6
133	Radiation dose escalation with modified fractionation schedules for locally advanced NSCLC: A systematic review. <b>2020</b> , 11, 1375-1385		7

132	Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis. <b>2020</b> , 20, 276	9
131	Radiation Esophagitis in a Patient with Oral Carcinoma and Bone Metastasis. <b>2020</b> , 14, 453-457	1
130	Genomic Analyses for Predictors of Response to Chemoradiation in Stage III Non-Small Cell Lung Cancer. <b>2021</b> , 6, 100615	2
129	Toxicity and survival outcomes in older adults receiving concurrent or sequential chemoradiation for stage III non-small cell lung cancer in Alliance trials (Alliance A151812). <b>2021</b> , 12, 563-571	3
128	Treatment strategies for locally advanced non-small cell lung cancer in elderly patients: Translating scientific evidence into clinical practice. <b>2021</b> , 163, 103378	2
127	Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer. <b>2021</b> , 21, 824	0
126	Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial. <b>2021</b> , 7, 1497-1505	4
125	Elderly Patients with Locally Advanced and Unresectable Non-Small-Cell Lung Cancer May Benefit from Sequential Chemoradiotherapy. <b>2021</b> , 13,	2
124	Lung Cancer. <b>2021</b> ,	
123	Surgical challenges in multimodal treatment of N2-stage IIIA non-small cell lung cancer. <b>2021</b> , 51, 333-344	4
122	Hollow PtCo alloy nanospheres as a high- and oxygen generating nanozyme for radiotherapy enhancement in non-small cell lung cancer. <b>2021</b> , 9, 4643-4653	6
121	Staging and prognosis in lung cancer: making the complex accessible. <b>2001</b> , 105, 53-94	5
120	Radiation therapy for non-small cell lung cancer (NSCLC). <b>2001</b> , 105, 121-48	2
119	New antineoplastic agents in lung cancer 1988-1993. <b>1994</b> , 323-347	2
118	Natural products as anticancer agents. <b>1994</b> , 42, 53-132	9
117	Issues in Data Analysis. <b>2015</b> , 403-462	2
116	Thoraxorgane. <b>2006</b> , 483-506	0
115	Toxicity and Efficacy of Treating Mediastinal and Hilar Lesions. <b>2007</b> , 177-192	1

114	Treatment Indications and Clinical Target Volume. <i>Medical Radiology</i> , <b>1999</b> , 225-239	0.2	2
113	Chemotherapie des nichtkleinzelligen Lungenkarzinoms. <b>1998</b> , 310-327		3
112	Radiotherapy for Non-Small Cell Lung Cancer. <b>1991</b> , 25-31		1
111	The Role of Systemic Chemotherapy in Non-Small Cell Lung Cancer. <b>1991</b> , 33-46		4
110	Nichtkleinzelliges Bronchialkarzinom. <b>1997</b> , 558-591		0
109	Cancer of the Lung: Non-Small Cell Lung Cancer and Small Cell Lung Cancer. <b>2008</b> , 1307-1366		4
108	DEFINITIVE MANAGEMENT OF INOPERABLE NONSMALL CELL LUNG CANCER. <b>2008</b> , 804-821		1
107	Interaction of Chemotherapy and Radiation. <b>2012</b> , 65-82		9
106	Cancer of the Lung. <b>2014</b> , 1143-1192.e13		3
105	Advances in the Treatment of Stage III Non-Small Cell Lung Cancer. <i>Clinics in Chest Medicine</i> , <b>2020</b> , 41, 211-222	5.3	9
104	Cisplatin, mitomycin, and vindesine followed by intraoperative and postoperative radiotherapy for stage III non-small cell lung cancer: final results of a phase II study. <b>1997</b> , 20, 276-81		11
103	Cisplatin and vinorelbine followed by radiotherapy in the treatment of stage III-B non-small-cell lung cancer patients. <b>1997</b> , 20, 404-6		12
102	Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06. <b>1997</b> , 20, 435-40		27
101	Tumor lysis syndrome and acute renal failure after treatment of non-small-cell lung carcinoma with combination irinotecan and cisplatin. <b>1998</b> , 21, 426-9		27
100	Cisplatin, ifosfamide, and vinorelbine combination chemotherapy in stage III-IV non-small-cell lung cancer: a phase II study. <b>1998</b> , 21, 518-22		14
99	Induction platinum-based chemotherapy followed by radical hyperfractionated radiotherapy with concurrent chemotherapy in the treatment of locally advanced non-small-cell carcinoma of the lung. <b>1999</b> , 22, 203-8		10
98	Mature results from a phase II trial of accelerated induction chemoradiotherapy and surgery for poor prognosis stage III non-small-cell lung cancer. <b>1999</b> , 22, 237-42		7
97	Long-lasting response to vinorelbine in unresectable non-small cell lung carcinoma: a case with concomitant good quality of life. <b>1998</b> , 316, 398-400		1

96	Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. <b>1996</b> , 224, 288-94; discussion 294-6	173
95	Combined-modality therapy in the nonsurgical management of unresectable stage III non-small cell lung cancer. <b>1999</b> , 5, 194-200	6
94	Neoadjuvant therapy: an emerging concept in oncology. <b>2005</b> , 98, 338-44	8
93	From Cisplatin-Containing Sequential Radiochemotherapy towards Concurrent Treatment for Patients with Inoperable Locoregional Non-Small Cell Lung Cancer: Still Unanswered Questions. <b>2010</b> , 2010, 506047	2
92	The Burgeoning Role of Paclitaxel in Advanced Pulmonary Malignancy. <b>1998</b> , 3, 67-85	2
91	Clinical and dosimetric factors of radiation-induced esophageal injury: radiation-induced esophageal toxicity. <b>2005</b> , 11, 2626-9	58
90	Chemotherapy for advanced lung cancer. When to expect a response. <b>1997</b> , 101, 187-8, 191-2, 194 passim	5
89	Definitive radiotherapy with or without chemotherapy for clinical stage T4N0-1 non-small cell lung cancer. <b>2015</b> , 33, 284-93	6
88	Dose escalation for unresectable locally advanced non-small cell lung cancer: end of the line?. <b>2016</b> , 5, 126-33	7
87	Treatment outcomes of three-dimensional conformal radiotherapy for stage III non-small cell lung cancer. <b>2005</b> , 37, 273-8	1
86	Clinical Responses and Prognostic Indicators of Concurrent Chemoradiation for Non-small Cell Lung Cancer. <b>2011</b> , 43, 32-41	8
85	EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy. <b>2019</b> , 51, 493-501	13
84	Lung cancer. <b>2005</b> , 25, 1-12	16
83	Concurrent chemoradiation for high-risk prostate cancer. <b>2015</b> , 6, 35-42	14
82	Types of Cancers Prevailing in Pakistan and their Management Evaluation. <b>2015</b> , 16, 3605-16	3
81	Chirurgie. <b>2000</b> , 33-43	
80	Internistisch-onkologische Therapie des nicht-kleinzelligen Bronchialcarcinoms. <b>2000</b> , 45-62	
79	Strahlentherapie. <b>2000</b> , 13-21	

- 78 Chemotherapy as an Adjunct to Surgery. **2001**, 1659-1676
- 77 Lung Neoplasms. **2001**, 1189-1216
- 76 Lung Cancer. **2001**, 177-204
- 75 Chemoradiation in locally advanced non-small cell lung cancer. **2001**, 105, 171-88
- 74 Combined modality therapy for early stage operable and locally advanced potentially resectable non-small cell lung carcinoma. **2001**, 105, 149-70
- 73 Non-Small Cell Lung Cancer. **2003**, 389-405
- 72 Nonsurgical Treatment of Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. **2003**, 142-157
- 71 Cancer biotherapy: 2003 disease-related activity. **2003**, 615-674
- 70 Strahlentherapie. **2004**, 425-463
- 69 Treatment Strategy for N2 Non-Small-Cell Lung Cancer:. **2005**, 45, 295-299
- 68 Nichtkleinzelliges Lungenkarzinom. **2006**, 3467-3584
- 67 Induction Therapy for Stage IIIA (N2) Lung Cancer. **2007**, 88-93
- 66 Advances in Chemoradiation Treatment of Locoregionally Advanced NonSmall Cell Lung Cancer. **2007**, 175-206
- 65 Image Guidance of Screening, Staging and Combined Modality Management of NonSmall Cell Lung Cancer. **2007**, 1-17
- 64 Combined Chemoradiotherapy Advances. **2008**, 277-301 1
- 63 Adjuvant and Neoadjuvant Radiation Therapy for Lung Cancer. **2010**, 263-265
- 62 Lung Cancer. **2010**, 287-293
- 61 Non-small Cell Lung Cancer. **2010**, 221-247 2



60	Tumors of the Lung, Pleura, and Mediastinum. <b>2010</b> , 737-771		1
59	Chemoradiotherapy for Inoperable Non-small Cell Lung Cancer. <b>2010</b> , 161-175		
58	Combined Modality Therapy in Cancer Management. <b>2011</b> , 483-517		
57	Sequential Designs for Clinical Trials. <b>2012</b> , 57-79		1
56	A phase I study with Satraplatin and simultaneous chest radiation for non-small cell lung cancer. <b>2012</b> , 01, 13-19		
55	Challenges in the management of stage III non-small-cell lung cancers. <b>2012</b> , 1, 301-308		
54	Radiotherapy in Lung Cancer. <b>2013</b> , 137-152		
53	Two Patients with Advanced Stage III Lung Cancer Completely Resected Following Concurrent Chemoradiotherapy (S-1 and CDDP) in Whom a Pathological Complete Response (CR) Was Obtained. <b>2013</b> , 53, 132-137		
52	Thoraxorgane. <b>2013</b> , 557-591		
51	Esophagus. <i>Medical Radiology</i> , <b>2014</b> , 325-351		0.2
50	Combined modality therapy for stage III non-small cell lung cancer : the University of Chicago experience. <b>1991</b> , 427-431		
49	Faster response and survival advantage with Neo-Adjuvant Cisplatin and 5-Fluorouracil infusion versus Cisplatin and Bleomycin in advanced non-small cell lung cancer. <b>1991</b> , 449-453		
48	Progress with Staging and Chemotherapy in Lung Cancer. <b>1993</b> , 89-94		
47	Cancer Forecasting: Cohort Models of Disease Progression and Mortality. <b>1993</b> , 109-136		1
46	CHEMOTHERAPY AND RADIATION FOR THE TREATMENT OF NONSMALL-CELL LUNG CANCER. <i>Clinics in Chest Medicine</i> , <b>1993</b> , 14, 161-171	5.3	11
45	Concomitant chemoradiotherapy with Cisplatin dose escalation as palliative therapy for advanced malignancies of the chest. <b>1994</b> , 370-374		1
44	Nicht- Kleinzellige Bronchialkarzinome. <b>1995</b> , 446-473		3
43	Lunge und Mediastinum. <b>1996</b> , 683-718		1

42 Lung Cancer. **1997**, 293-303

41 Phase II Clinical Trials in Oncology. **1997**, 249-270

40 Issues in Data Analysis. **1998**, 284-322

39 Non-Curative Chemotherapy for Non-Small Cell Lung Carcinoma. *Focus on Cancer*, **1998**, 215-229

38 Induction or Concurrent Chemotherapy and Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. *Medical Radiology*, **1999**, 85-94 0.2

37 New Drug Combinations in NSCLC: Progress in Cancer Therapy. **1999**, 131-174

36 Basic Biostatistical Methods in Oncology: Principles of Clinical Research Methods. **1999**, 1186-1201

35 Fractionation as a Biological Dose Modifier. *Medical Radiology*, **1999**, 151-159 0.2

34 Progress and Perspectives in the Chemotherapy of Epithelial Solid Tumors. **1999**, 21-33

33 Nicht kleinzelliges Bronchialkarzinom im Stadium IIIA: Rolle der Bestrahlung im adjuvant/neoadjuvanten Therapiekonzept. *Langenbecks Archiv Fu r Chirurgie Supplement*, **1999**, 139-144

32 Advances in Radiotherapy for Locally Advanced NSCLC. **2015**, 69-94

31 Non-small Cell Lung Cancer. **2015**, 249-260

30 Esophagitis. **2017**, 125-132

29 Lung Cancer. **2019**, 197-232

28 ??????????????????????: ??????????????????. *The Japanese Journal of SURGICAL METABOLISM and NUTRITION*, **2019**, 53, 185-189 0

27 Combined chemoradiotherapy regimens and their effectiveness in the treatment of patients with non-small-cell unresectable stage III lung cancer: review of literature. *Meditinskiy Sovet*, **2019**, 92-98 0.4

26 ERKRANKUNGEN DER ATMUNGSORGANE. **2020**, C-1-C22-4

25 Lung Cancer. **2003**, 441-454 0

24	Integration of Radiotherapy in the Management of Locally Advanced Non-Small-Cell Lung Cancer. <b>2006</b> , 237-247		
23	Secondary Primary Cancer Following Chemoradiation for Non-Small-Cell Lung Cancer. <b>2008</b> , 261-267		
22	Lung Cancer. <b>2006</b> , 141-155		
21	Nichtkleinzellige Lungenkarzinome. 588-614		
20	Immunotherapy for Lung Cancer-Improving Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer With Immunotherapy. <i>Cancer Journal (Sudbury, Mass )</i> , <b>2020</b> , 26, 548-554	2.2	0
19	Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. <i>BMJ: British Medical Journal</i> , <b>1995</b> , 311, 899-909		524
18	Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer. <i>Core Evidence</i> , <b>2007</b> , 2, 31-49	4.9	3
17	Unresectable stage III non-small cell lung cancer: is Tecemotide a new START for our patients?. <i>Journal of Thoracic Disease</i> , <b>2014</b> , 6, 574-7	2.6	2
16	P53 Vom prognostischen zum prädiktiven Marker. <i>Acta Chirurgica Austriaca</i> , <b>2000</b> , 32, 68-72		
15	Recent progress in optimizing radiotherapy in chemo-radiotherapy for stage III non-small cell lung cancer. <b>2002</b> , 4, 9-22		
14	Combined Radiation Therapy and Chemotherapy as an Exclusive Treatment Option in Locally Advanced Inoperable Non-small Cell Lung Cancer. <i>Medical Radiology</i> , <b>2021</b> ,	0.2	1
13	Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , JCO2102528	2.2	7
12	Data_Sheet_1.docx. <b>2018</b> ,		
11	Trimodality therapy for patients with stage III non-small-cell lung cancer: A comprehensive surveillance, epidemiology, and end results analysis.. <i>Cancer Treatment and Research Communications</i> , <b>2022</b> , 32, 100571	2	
10	Hematological Toxicity in Lung Cancer. <i>Medical Radiology</i> , <b>2022</b> ,	0.2	
9	A review of concurrent chemo/radiation, immunotherapy, radiation planning, and biomarkers for locally advanced non-small cell lung cancer and their role in the development of ECOG-ACRIN EA5181. <i>Clinical Lung Cancer</i> , <b>2022</b> ,	4.9	
8	Genomic Profiling Reveals Novel Predictive Biomarkers for Chemo-Radiotherapy Efficacy and Thoracic Toxicity in Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 12,	5.3	
7	Combined Radiotherapy and Chemotherapy: Theoretical Considerations and Biological Premises. <b>2022</b> ,		1

- 6 Chemotherapy for Lung Cancer. **2022**, ○
- 5 Cancer of the Lung. 1-29 ○
- 4 NKp44-Derived Peptide Used in Combination Stimulates Antineoplastic Efficacy of Targeted Therapeutic Drugs. **2022**, 23, 14054 ○
- 3 Research landscape and trends of lung cancer radiotherapy: A bibliometric analysis. 12, ○
- 2 Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer. 13, ○
- 1 Development and validation of machine learning models to predict survival of patients with resected stage-III NSCLC. 13, ○